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ABSTRACT
Often, machine learning and big data concepts are applied to problems with-
out a proper appreciation of their limitations or domain context. At the same
time there is a growing appreciation for the ability of networks to represent
more complex connections between data points than previous structures.
However, established machine learning approaches rarely take advantage of
such structures and must be adapted. We present here a method that uti-
lizes patterns of connections within heterogeneous networks to score items
by their similarity to an input set. We apply the idea of meta-paths as an
abstraction to counteract typical big data problems of noise and overfitting.
We also aim to demystify the black-box nature of machine learning by pro-
viding intuitive feedback about why items are considered similar. While the
method presented here is generalizable to any domain, the specific examples
explored are within the genomics domain. The final tool, GeneSet MAPR,
is especially useful in a domain with little ground truth and a huge volume
of noisy, uncertain data. We show that GeneSet MAPR performs better at
discovering related but concealed data points than an approach using the
same data without abstraction, as well as a an established state-of-the-art
approach that works on a network but ignores the heterogeneous patterns.
It does this while providing details the other methods cannot.
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CHAPTER 1
INTRODUCTION
1.1 Motivation
Suppose one has a dataset — say, our mother’s music collection — to which
we wish to contribute. First, we need to understand the collection. Which is
more representative of her taste: the Phish albums, the Motown collection,
or the Bing Crosby she plays for the holidays? We have imperfect metrics to
define her preferences: how often she plays an album, or how much dust is on
the cover. But we also have a vast wealth of outside information, details for
every album including genre, artists, era, which band plays another’s covers,
whose band members have played together, when and which songs appear
on the Billboard Hot 100 or Prairie Home Companion, and much more.
Here we present an approach that leverages established domain knowledge
to learn what makes a dataset unique, and applies the patterns from within
that dataset to find other similar items, so one may buy Mom the perfect
birthday present. Of course, this also generalizes to other applications.
The problem can be thought of as one of set membership, where some
outliers are less representative of the set as a whole and many items which
should belong in the set are yet to be discovered. Similar datasets exist
in many domains: biology, movie-streaming services, social networks, book
sellers, and personalized clothing. Today there is even a company whose
focus is on recommending the perfect coffee! In every case, a set of provided
items is deemed to be important. The first challenge, then, is in setting
an objective function that captures the uniquely identifying characteristics
within the set, based on a compendium of a priori domain knowledge. The
second challenge is to avoid over-fit, where noisy, inconsequential details
nonetheless show some correlation to the problem at hand, such as using the
Super Bowl winner to predict the stock market [1]. An effective next step is
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to arrange the domain knowledge in the form of a network (or graph) [2, 3, 4].
Networks are used in many domains to represent a collection of items which
share pair-wise relationships, and readily allow for the formal quantification
of higher-order relationships between items.
This problem has similarities to both personal recommendation and com-
munity detection. Unlike personal recommendation, which is often more
interested in marketing a diverse array of products or media in an effort to
entice a user, we wish to be more careful about Type I error, or the erroneous
inclusion of items which should not belong. We also wish to return an intu-
ition for what it is that makes the set unique. In community detection, one
attempts to cluster all items in a network into semantic groups, identifying
and separating unique chunks [5, 6]. Older methods tended to require the
user to provide an expected number of clusters while newer methods, rec-
ognizing the problem of such an upfront requirement, attempt to use ideas
such as cut-minimization, flow, or spectral partitioning to learn the optimal
number of clusters in an unsupervised manner [7]. For example, depending
on the fashion at time of publication, in academic literature terms such as
Machine Learning and Artificial Intelligence may be used interchangeably
or may instead refer to distinctly separate processes. Applying a commu-
nity detection algorithm may uncover modules within that literature with
distinct algorithmic approaches, such as might be seen in the fields of Sig-
nal Processing versus Robotics versus Computer Vision. While the goal of
community detection is to optimally categorize all items in the network, we
wish to apply a semi-supervised approach that takes a user’s input and finds
the items most likely to belong in the cluster represented by that set. What
other clusters, or how many, may exist in the network is not our concern.
To this end, we present Geneset MAPR (Meta-path Analysis for Pattern
Regression) an algorithm that learns the patterns of connectedness within
a set, based upon a network containing various types of domain knowledge.
MAPR then applies those patterns to give a probabilistic score to all items
in the network based on how similar they are to the input set. Whereas
it is common for a network-based similarity measure to use a network of
homogeneous relationships or otherwise make no real distinction between
them [8], MAPR leverages the ideas of meta-paths and connectedness to
explicitly account for the heterogeneous nature of underlying relationships.
Meta-paths allow us to apply a level of abstraction to the data — smoothing
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noise in favor of broader trends — while providing a quantifiable network-
based pattern from which we can create a set’s identifying fingerprint. An
item is deemed similar to the set if the pattern of connectedness joining it
to the set is similar to the uniquely representative pattern for items already
included. Meta-paths have been shown to be useful for community detection
in the academic literature domain, provided a user specifies the number of
clusters, a few items to seed each cluster, and a small set of interesting meta-
paths [9, 10]. However, one of our primary goals is to remove from the user
the responsibility for choosing appropriate meta-paths (while leaving open
the possibility for a user to later weight the returned meta-paths according
to her own preference). As mentioned, we also omit the requirement to pre-
select a number of clusters; defining an optimal number of clusters is a very
subjective problem whose answer is very dependent on context. Our goal
is to return how likely an item is to belong in the user’s preferred cluster.
While GeneSet MAPR was developed to apply these ideas to the genomics
domain, the framework is readily generalizable with little to no adaptation
to existing code.
1.2 GeneSet MAPR and the Genomics Domain
Gene set analysis is a mainstay of modern functional genomics studies. Rela-
tively fast, high-throughput experiments enable a researcher to quickly iden-
tify a set of genes based on a preferred metric, such as gene expression levels,
altered epigenomic states, or signatures of selection in coding sequences. For
example, differential expression may then be compared between patients who
recovered after a given treatment versus those who did not in order to define
a phenotype. Such measures are typically supplemented with a p-value, an
estimation of how unlikely it is that an observation is due to random chance.
Given such a gene set, a researcher will attempt to learn its relevant prop-
erties. This is commonly done by comparing overlap with established but
continuously evolving functional annotations, such as gene ontology terms or
protein domains. A term that has high overlap with the gene set is said to be
enriched for the set. The most basic example of this would be Fisher’s exact
test, but tools such as DAVID and GSEA offer somewhat more advanced
enrichment analysis with the advantage of convenient interfaces.
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In the genomics, and the field of bioinformatics more generally, ground
truth can be hard to come by. Experimental validation of a finding often
requires expensive, targeted experiments with long lead times. Additionally,
clinical trials often suffer from small sample sizes, and focusing on a particu-
larly lethal or specialized variation of a disease makes it even harder to find
participants. Obviously, a small sample size makes measures of magnitude,
such as differential expression, more susceptible to noise in the data. Further-
more, there can at times be a misplaced reliance on statistical significance,
or p-value, as a hard threshold without accounting for the statistical power
of the study or other factors [11, 12]. In the worst case there may be bias
towards presenting results that conform with other published research, and
are therefore considered more believable.
Notably, the types of measurements that lend themselves to a high-throughput
setting are often unrelated to causality. For example, a biological process of-
ten relies on a series of interactions between genes, and an upstream mutation
in one gene may cause a change in the expression levels of several other genes.
The downstream genes may be flagged by the chosen experiment while the
upstream gene — the cause of the change — is not. Ideally, we wish to find
the pattern of connectedness between genes in the user-provided set that
guides a researcher to overlooked genes that nonetheless belong in the set,
allowing her to spend limited resources more efficiently.
GeneSet MAPR applies a set membership approach to gene set analysis,
leveraging not only multiple varied networks of gene annotations, but also
many disparate forms of gene-gene relationships. This can be thought of
as establishing a weighted combination not only of enriched terms, but of
whole bodies of research that is uniquely descriptive of an input gene set. In
the field of bioinformatics, networks exist representing relationships between
patients, diseases, genes, processes, some combination of these, and more.
Here, we concern ourselves specifically with networks encoding interactions
and relationships at the gene level. We make no judgments as to the quality
of the networks; rather, we accept them as established knowledge that will
help to better understand the gene sets in question. Of course, the quality
of underlying networks does matter, but as shown later in this thesis the
approach used by MAPR is able to emphasize data that is relevant to a
user’s input set.
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1.3 Outline
Before outlining and evaluating GeneSet MAPR, this thesis first reviews
necessary concepts pertaining to networks in Chapter 2, culminating in the
definition of meta-paths. Next, the networks upon which MAPR was tested
along with their sources are detailed in Chapter 3. Chapter 4 describes the
approach used by MAPR, while Chapter 5 presents an array of evaluations
to validate and elucidate its performance, including comparisons with state-
of-the-art approaches to this problem that have been applied in the genomics
domain. A real-world application to a novel, newly defined gene set appears
in Chapter 6. Finally, proposed next steps and concluding remarks follow.
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CHAPTER 2
NETWORK STRUCTURE AND
META-PATHS
GeneSet MAPR considers relationships between genes in a set in order to gain
an understanding of what makes the set unique from the rest of the genome.
Therefore, it requires some collection of accepted knowledge upon which to
draw, even as we grant that such knowledge may contain imperfections. In
mathematics, a structure representing a collection of items sharing pair-wise
relationships is called a graph. In many other domains, it is frequently termed
a network. So, too, do the names of components within such a structure
differ between domains. Therefore, we will now introduce the terminology
to be used for the rest of this paper as we build towards the definition of a
meta-path, the utility of which is the hypothesis underlying GeneSet MAPR’s
development.
Readers interested in a deeper understanding of graph theory, including
proofs and additional concepts are encouraged to see [13, 14].
2.1 Basic Network Terminology
In biology, the word network is often used to describe what is formally known
in mathematics as a graph, the most basic component of which is called a
vertex, or node. An example can be seen in Figure 2.1. Each node represents
a discrete data point, and a network encodes the relationships between them.
In the context of this thesis, nodes may represent either a specific gene or
a non-gene term that describes some shared relationship among a group
of genes, such as ontological annotations, protein families, or interaction
pathways.
A relationship between a pair of nodes is represented by an edge. For ex-
ample, each gene belonging to a given protein family — a non-gene term —
will be connected to that family node via an edge. The degree of a node is
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Figure 2.1: A simple network showing examples of nodes, edges, a walk,
and a cycle.
the number of edges connecting to, or shared by, that node. In this case, the
node for a large family may have a degree of 1,000 or so, as it will have a sep-
arate edge connecting it to each of its member genes. Meanwhile, a typical
gene node will have a much lower degree, as its membership has only been
confirmed for a handful of protein families, and thus it only shares a handful
of edges. A small number of nodes corresponding to well-studied genes have
a much higher degree, as more relationships have been experimentally dis-
covered. Nodes with exceptionally high degree are called hub nodes. What
constitutes a hub node is contextual, but generally it is a node whose de-
gree far exceeds what would be expected if all the edges in a network were
randomly distributed.
Edges may be directed, representing a one-way relationship. A relationship
that is mutual, or reciprocal, is represented by an undirected edge. For
example, if two genes in a homology network share an ancestral origin, then
their corresponding nodes will be connected by an undirected edge indicating
that shared, mutual relationship. In contrast, if one gene acts upon another,
or if an ordered series of relationships is important, a directed edge will
connect the origin gene to the terminus. As mentioned in Chapter 1, we are
interested in discovering both upstream and downstream genes: those that
may have caused the observed behavior as well as those that may be affected
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by it. As such, the GeneSet MAPR method presented in Chapter 4 treats
all relational edges as undirected.
Edges may have a weight. The weight may be binary, where the presence
of an edge indicates merely the existence of the specified relationship. In this
case, the weight is 1. Alternatively, edge weight may indicate the strength of
a relationship, the frequency of its occurrence, or the confidence that a gene
truly belongs in the specified protein family. In such a case, the lack of a
connecting edge between two nodes has the same implication as creating an
edge with a weight of 0: there is no observed relationship between those two
nodes.
Many pairs of nodes may not share any edges; that is, they may not be
directly connected. However, they may share an indirect, multi-step connec-
tion called a walk, where an originating node shares an edge with a second
node, which shares an edge with a third node, and so on until reaching the
specified terminal node. There may exist many unique walks connecting the
two nodes, each passing through different sets of nodes and edges along the
way. A path is similar, except that it specifies only the edges encountered at
each step along the walk. Path length denotes the number of edges that are
part of the path. A cycle refers to a walk or path that begins and ends at
the same node. A path itself may not be a cycle while nonetheless containing
one. A simple path denotes the absence of any such cycles: no nodes or edges
are repeated.
2.2 Homogeneous and Heterogeneous Networks
Edges may have an additional property called type. This is used when an
individual edge in the network may represent one of several disparate types of
relationships. For example, two gene nodes may share several different edges,
as they may be related through homology, direct protein-protein interactions
(PPI), and frequent co-occurrence in published research. Separate edges
would be used to indicate each relationship, with corresponding edge types
of homology, direct PPI, and textmining. Each edge would be weighted
according to the methodology for its respective edge type, and prior to any
standardization the edge weight is relative only to other edges of the same
type.
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In many networks, all edges are of the same type. Such a network, termed
homogeneous, describes a uniform collection of interactions between similar
objects. A heterogeneous network, on the other hand, describes a network
consisting of multiple types of edges and nodes. In the KnowEnG network
introduced in Chapter 3, gene nodes may be interconnected via homology
or interaction edges, and may also be connected to non-gene term nodes via
ontology or protein family edges. Heterogeneous networks introduce a wider
range of independent observations, but require different considerations than
homogeneous networks.
A subnetwork of a given network N is the network formed when only a
subset of edges and nodes from N are used. Unless otherwise specified, in this
paper we will use subnetwork to refer to the homogeneous network induced
by extracting all edges of a specific type. That is, one could think of the
heterogeneous network of multiple typed edges as having been constructed
from the union of several homogeneous subnetworks, as N = {N t1 ∪ N t2 ∪
N t3∪ . . . }. Any nodes connected to those extracted edges are also considered
a part of the subnetwork. Thus, for our purposes, specific nodes may appear
across multiple subnetworks but an individual edge will belong only to the
subnetwork of corresponding edge type.
An illustration of combining two homogeneous subnetworks into a single
heterogeneous network can be seen in Figure 2.2.
2.3 Meta-Paths
We are interested in evaluating structural patterns between nodes in a way
that incorporates the heterogeneous nature of the relationships contained.
However, we also wish to ensure the evaluations can be done with reasonable
computational efficiency and robustness to noise. To this end, we explored
the use of an abstraction termed meta-paths.
The objective in using meta-paths is to describe potential paths of varying
lengths between nodes at the meta level — a higher level of abstraction than
individual edges. A meta-path defines a new form of relationship between
nodes of the same type as a composite of specified edge types [9]. That is,
for a network comprised of a collection of multiple edge types {t1, t2, . . . }, a
meta-path m specifies the ordered series of edge types which must be tra-
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(a) (b)
(c)
Figure 2.2: (a) and (b) show homogeneous subnetworks, each with its own
set of connections over the same set of nodes. (c) shows the combined
heterogeneous network with edge type, or originating subnetwork, specified
by color. Supposing meta-path m1 is defined as (orange, purple), we
observe that node 6 is connected via m1 to nodes 2, 3, 4, 5, and 8, ignoring
cycles. Following the inverse meta-path m−11 = (purple,orange), node 6 is
connected via m−11 to nodes 7 and 8.
versed for the connecting path to be considered. For example, consider a
network containing two edge types: homology (Ho) and protein interaction
(Pi). Suppose we define meta-path m1 = (Ho, Pi, Ho), where the relation-
ship described by m1 is one where the origin and terminus genes each have a
homologous gene (related through ancestry) that share a physical interaction
at the protein level. Thus, our analysis of m1 would only consider connec-
tions between genes where the edges along the path follow the pattern (Ho,
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Pi, Ho). We could then specify a collection of meta-paths M = {m1,m2, . . . }
which are deemed of enough interest to warrant investigation. An illustration
of meta-paths in a heterogeneous network can be seen in Figure 2.2.
Supposing the edges in the network are all undirected, a symmetric meta-
path is one where the specified order of edge types is itself symmetric. Thus,
if gene g1 connects to gene g2 along the symmetric meta-path m1 = (t1, t2, t1),
then the reverse is true. That is, g1
m1−→ g2 implies g1 m1←− g2. However, this is
not the case for an asymmetric meta-path, such as m2 = (t1, t2). So we will
define an inverse meta-path as one where the order of edge types is reversed,
such that m−12 = (t2, t1). It follows that in the case of asymmetric meta-path
m2, g1
m2−→ g2 implies g1 m
−1
2←−− g2.
In Chapter 4, we outline a method that collects and compares the number
of paths connecting genes within an input set, provided those paths follow
the pattern of edge types described by select meta-paths. As short-hand,
we will often refer to two genes as connecting along meta-path m if they are
connected by one or more paths of the pattern specified by either m or m−1.
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CHAPTER 3
THE KNOWENG NETWORK
The GeneSet MAPR method explored in Chapter 4 and the tools against
which it was evaluated require networks upon which to run, to be used as
compendia of a priori knowledge. For this, we use the networks collected
for use by KnowEnG (Knowledge Engine for Genomics), outlined in Ta-
ble 3.1. MAPR was designed to be part of the suite of tools available on
the KnowEnG platform developed here at UIUC (University of Illinois at
Champaign-Urbana) and funded by the NIH (National Institutes of Health).
For use with its network-based analytics tools, KnowEnG has collected data
from many large, publicly available sources.
For the development and evaluation of GeneSet MAPR, nine distinct sub-
networks were extracted, representing a wide range of potential relationships
and annotations. Some, such as Gene Ontology, are widely accepted ways
of understanding studied relationships. Some, such as Textmining, are much
less traditional. While the networks used by KnowEnG have undergone con-
tinued refinement and expansion over the past two years, the beta versions
of the networks used to evaluate MAPR were frozen at the start of its devel-
opment. This ensured fair comparisons of MAPR to previous states, as well
as to the state-of-art network-based DRaWR in Chapter 5. One exception to
this is the Homology edge, and the reason for the update will be addressed
below.
3.1 Network Contents
3.1.1 Shared Annotations
Three of the subnetworks used in this paper represent gene annotations.
When a group of genes have all been found to share some association — such
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Table 3.1: Summary of Subnetworks
Subnetwork Terms Weight Source Description
coexpression n probabilistic STRING predicted association based on expres-
sion pattern
GO: Bio Proc y 1 or 2 GO Cons. larger processes composed of multiple
gene products
GO: Cel Comp y 1 or 2 GO Cons. regions where gene products are active
GO: Mol Func y 1 or 2 GO Cons. molecular activities of gene products
homology n −log10(E) BLAST shared ancestry between a pair of
genes
pathway y binary KEGG series of genes contributing to cellular
behavior
PPI: direct n binary DIP direct protein-protein interaction
PPI: genetic n binary DIP genetic protein-protein interaction
PPI: physical n binary DIP physical similarities between proteins
Protein Fam y −log10(E) Pfam protein domain: indicates relationship
through evolution
textmining n probabilistic STRING statistically relevant co-occurrences in
scientific texts
as all playing a significant role in brain development, or interacting in the
same signaling pathway — the genes in that group are all labeled with that
specified annotation. Individual genes typically share many annotations,
which can vary greatly by size and the amount by which the annotations
overlap. In these respective subnetworks, the annotations are represented as
non-gene nodes, which will also be referred to as term nodes.
In this version of the KnowEnG network, each of the annotation subnet-
works is bipartite. In a bipartite network, the nodes can be separated into
two groups, where edges connect nodes from one group to another, but do
not connect nodes within either group. So in these subnetworks there are
gene nodes and term nodes. Every edge in the network connects to both a
gene node and a term node, never joining two nodes of the same type. Term
nodes may have a degree anywhere between a few and several thousand edges,
representing all of the genes belonging to that annotation term.
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Gene Ontology
The Gene Ontology (GO) project set out to define an ontology — a rep-
resentation of collected knowledge — regarding genes and their functions.
The explicit goal was to provide a structured and controlled vocabulary for
use in gene annotation that was biologically meaningful and unified across
species [15]. Ontology terms and definitions are made available through the
GO Consortium.
In the KnowEnG network, a GO edge has two possible edge weights.
A value of 2 indicates an experimentally supported annotation, where the
association between a gene and the function described by a GO term is
shown through direct experimentation and supported through published,
peer-reviewed research. A value of 1 indicates an inferred relationship, where
a gene’s GO annotation is inferred from the annotation of other genes within
the same family, or with a shared biological ancestry.
It should be noted that the functions described by GO terms can be re-
lated to each other, resulting in a hierarchical network. At the top are three
terms, each describing a different potential aspect of any given function.
Terms falling under molecular function describe activities at the molecu-
lar level. Cellular component terms refer to the location within cellular
anatomy where a molecular function is carried out. A biological processes
term describes a multi-step series of events involving one or more molecular
functions. This is not the same as a pathway, which is discussed next. In
conversations with biologists, it was suggested that these three aspects are
distinct enough that we may wish to separate the GO network into three
respective subnetworks, based on these top-level terms. Indeed, this change
brought two benefits: providing more intuitive edge types for describing how
sets are connected, and immediately improving GeneSet MAPR’s ability to
predict hidden members of a set, an evaluation metric explored in Chapter
5. The GO subnetwork used for this paper did not incorporate relational
edges between GO terms, thus the hierarchical nature of the GO network
was not addressed by MAPR. Chapter 7 discusses how this could potentially
be incorporated.
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Pathway, KEGG
A pathway describes a series of inter-dependent actions effecting some change
in or product produced by a cell. For example, activating a pathway may
result in turning a gene off, or assembling a new protein. Common pathways
relate to metabolism, gene regulation, and signaling. A pathway term node
shares edges with all genes involved in that series of interactions. Edges
are binary, indicating that each specified gene has been implicated in that
respective pathway.
KnowEnG collected terms in this subnetwork from the Kyoto Encyclope-
dia of Genes and Genomes (KEGG) [16], a pathway database established
by Kyoto University. Each manually drawn pathway relates molecular-level
information to higher-level functions and utilities through genes and their
products.
Protein Domain, Pfam
A domain specifies a distinct region on a protein sequence that is stable and
can fold independently of the rest of the protein. A specific domain may
appear across many proteins, in varying combinations with other domains.
Edges in the subnetwork indicate an association between a given gene and
family of protein domains. Edge weights are continuous values based on the
Expect value, which describes the expected number of matches found by
making a similar random selection from a database of the same size. The
closer to zero the Expect value, the more significant the match. Final edge
weights are the negative log 10 of the Expect value.
This subnetwork comes from Pfam, produced at the European Bioinfor-
matics Institute [17]. Pfam uses hidden Markov models to identify and align
protein domain family members.
3.1.2 Direct Relationships
The remaining subnetworks each represent a specific type of direct gene-
gene relationship. That is, the nodes in each represent individual genes
and nothing else. Edges exist between a pair of genes only if the specified
interaction between the two has been observed, or otherwise inferred.
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Homology, BLAST
Homology refers to the existence of a shared ancestry between two genes,
which have since evolved independently. Similar to the protein domain sub-
network, edge weights are negative log 10 of the Expect value. Edges were col-
lected from Protein BLAST (Basic Local Alignment Search Tool), or Blastp,
created by the U.S. National Library of Medicine [18].
The homology subnetwork was the only one to be updated over the course
of GeneSet MAPR’s development. We noticed during evaluations that the
homology subnetwork consistently showed little to no positive impact on
results across all tested gene sets, as compared to other subnetworks. Further
examination showed it was surprisingly sparse — containing many fewer
edges than would have been expected — suggesting a poorly defined threshold
or other issue when the subnetwork was collected. The KnowEnG network
had undergone many changes in the meantime, so we swapped in the Blastp
homology subnetwork and re-ran the evaluations, noting an improvement in
the results.
Protein-Protein Interactions
Processes within a cell often result from the interaction of many proteins.
Such a Protein-Protein Interaction (PPI) generally designates a chemical re-
action catalyzed by two or more proteins in close physical proximity. There
are different categories of PPI, and they may be measured or deduced using
different techniques. Here, three types of PPI are considered, each of which
is represented by its own subnetwork: direct interaction, genetic inter-
action, and physical association. In each case, edge weights are binary,
representing merely the existence of a relationship.
All three networks were collected from the Database of Interacting Proteins
(DIP), compiled by the University of California, Los Angeles [19].
Textmining, STRING
Textmining represents a much different approach to automatically inferring
and collecting gene-gene interactions. Here, an automated process scans
Medline abstracts as well as a significant number of full-text articles, uncov-
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ering both semantic connections between genes and statistically significant
shared occurrences [20]. Edge weights are based on a probabilistic score com-
bining evidence from multiple channels while adjusting for the likelihood of
randomly observed interactions.
KnowEnG collected textmining edges from the STRING database (Search
Tool for the Retrieval of Interacting Genes/Proteins), a collection of known
and predicted functional interactions [20].
Coexpression, STRING
The coexpression subnetwork is perhaps the most unconventional network
used in this thesis. Here, shared edges represent gene-gene interactions pre-
dicted by algorithmic analysis of genomic information, as well as analysis of
simultaneous gene expression (hence, coexpression) [20]. As STRING is the
source of this subnetwork, edge weights are based on the same probabilistic
scoring method as the textmining subnetwork.
3.2 Distribution of Node Degree in Network
A scale-free network is one wherein, with respect to node degree, there exists
no “typical” node according to which the rest can be characterized [21].
There is such variance in the number of edges connecting to individual nodes
that the network lacks a relative scale. This means there is an exceptionally
high number of nodes with very few connections, yet also a high occurrence
of nodes with a degree far greater than the average. Scale-free networks are
common in many domains, and biology is no exception [22]. In fact, the
KnowEnG network used in this thesis follows a similar distribution. The
median node degree in the network is 69, while the mean is nearly twice that
at 127.7.
In many ways, this imbalance is to be expected. Some genes and processes
have a much longer history of focused study than others, and that history can
in turn influence where a researcher chooses to spend her limited resources,
compounding the issue. The result is that some genes have a wealth of
established, experimentally proven connections while there is less incentive
to study those that are much less established.
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(a) (b)
Figure 3.1: Histogram of nodes in KnowEnG network by node degree.
Right is a log-log transformation of the left figure. The dotted line shows
an exponential function fitted to the raw counts of nodes.
Figure 3.1(a) shows the histogram of KnowEnG network nodes by degree,
and an exponential function that has been fitted to the distribution. Indeed,
the distribution of node degree approximates the power law distribution,
more easily seen in the log-log scaling of Figure 3.1(b). Such networks can
prove challenging to work with, as hub nodes may wield undue influence,
and divining useful information from a collection of very sparsely connected
nodes may prove difficult. One goal of GeneSet MAPR is to put these genes
on a more equal footing, such that a researcher may be guided to invest
time in — and discover fruitful connections to — genes which are currently
less-understood. The approach taken by MAPR to address this is outlined
in Chapter 4, and an evaluation of the final result appears in Chapter 5.
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CHAPTER 4
GENESET MAPR
Here, the approach used by GeneSet MAPR is described in detail. The goal
of MAPR is two-fold: to learn the pattern of relationships connecting genes
within a set, and to use that learned pattern to rank all available genes by
their similarity to the set. The process by which this is done revolves around
quantifying the connections along meta-paths in a heterogeneous network of
a priori knowledge.
To this end, GeneSet MAPR performs three primary steps. First, the
heterogeneous network is pre-processed to speed up the retrieval of meta-
path counts. Second, meta-paths are used to define an abstracted pattern of
connectedness within a gene set, to be used as set-specific features. Third,
genes are ranked by their connectedness to the set using an ensemble of
LASSO regressions.
There are a few challenges posed by the genomics domain to any classifi-
cation or similarity algorithm that GeneSet MAPR must overcome. Robust-
ness is one. For instance, the observations in the underlying networks will
be subject to some noise: errors in measurements as well as, in some cases, a
shifting understanding of gene-gene interactions and their import. Addition-
ally, some genes and their products have been the focus of much more study
than others, resulting in unbalanced subnetworks, where a few hub nodes
have hundreds or thousands of connecting edges while most nodes have less
than 50. By viewing the network in terms of meta-paths, MAPR introduces a
level of abstraction that helps smooth noise at the level of individual edges.
As for hub nodes, their out-sized influence is mitigated through both the
gene-relative transition matrices (Section 4.2) and path-relative connected-
ness score (Section 4.3); a quantitative examination regarding influence of
node degree is provided in Chapter 5.
The gene sets themselves may be noisy as well: they are often created
by applying a threshold to one or more measurements, whose values may be
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(a) convert meta-paths to transition matricies
(b) calculate connectedness to gene set
(c) train ensemble of classifier models
Figure 4.1: Overview of GeneSet MAPR
derived from a small number of study participants. Thus, there is uncertainty
in which genes are deemed part of the positive set. Furthermore, unlike
classical machine learning formulations, there is no representative negative
set. What GeneSet MAPR is presented with, then, is a positive set —
the input gene set — typically of around 50–500 genes. In the case of the
human genome, this is out of 23,782 genes with connections in the KnowEnG
network, the rest of which are treated as unlabeled. MAPR approaches
these challenges by training an ensemble of classifiers, and sub-sampling the
unlabeled and positive sets as necessary (Section 4.4).
A visual reference of MAPR’s primary steps can be found in Figure 4.1.
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4.1 Conversion of Indirect Connections
Table 4.1: Edge Counts Before/After Conversion
subnetwork original edges term nodes converted edges edge type in network
coexpression – – 50, 100 STRING coexpression
GO: Bio Proc 142, 699 10, 905 16, 773, 233 GO BioProc
GO: Cel Comp 71, 627 1, 476 73, 632, 134 GO CelComp
GO: Mol Func 62, 624 3, 815 48, 104, 940 GO MolFunc
homology – – 652, 823 blastp homology
pathway 24, 878 299 2, 292, 622 kegg pathway
PPI: direct – – 86, 569 PPI direct interaction
PPI: genetic – – 2, 487 PPI genetic interaction
PPI: physical – – 184, 435 PPI physical association
Protein Fam 71, 324 3, 631 5, 423, 388 pfam domain
textmining – – 354, 931 STRING textmining
total 373, 152 20, 126 147, 557, 662
As discussed in Chapter 3, the network of a priori data used during evalua-
tion of GeneSet MAPR consists of 11 subnetworks, each describing a different
relationship type or observation methodology. Five of those subnetworks con-
sist of shared annotations, rather than direct gene-gene relationships. In this
section, such subnetworks will be referred to as containing indirect connec-
tions, where a gene-gene connection must pass through an annotation, or a
term node.
Subnetworks consisting of indirect connections pose a philosophical co-
nundrum. We initially wish to remain agnostic to the types of underlying
subnetworks, giving equal weighting to each, while leaving open the possibil-
ity for the end-user to later specify the importance they wish to apply to a
given subnetwork. In the case of meta-paths, an indirect gene-gene connec-
tion must be represented by two steps along the same edge type, as opposed
to just one for a direct connection. However, since these indirect subnetworks
are all bipartite, they can easily be reduced to direct gene-gene connections.
For a bipartite subnetwork of indirect connections, GeneSet MAPR con-
verts each annotation term along with all of its shared edges into a corre-
sponding set of gene-gene edges. If two genes each share an edge with the
same annotation, those two edges will be replaced with a single edge between
those two genes. Edge weights are normalized per subnetwork to the range
[0, 1] and treated as the confidence in the existence of a particular edge —
a probabilistic estimate that the annotation or relationship is accurate. The
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Figure 4.2: Simple example of converting indirect gene-term edges into
direct gene-gene edges. Left is the original subnetwork with two annotation
terms. Right is the final result, where edge weights between two genes are
the product of the two indirect edges connecting them.
weight of the new edge is the product of the weights of the two replaced edges.
Hence, each gene then shares a direct connection to every other gene anno-
tated by the same term, where the new edge weight is the joint probability
that the two genes share that annotation. If two genes share multiple anno-
tations, then one new edge will be created between them for each annotation.
An example of this conversion can be seen in Figure 4.2.
Table 4.1 shows each subnetwork used in this thesis, along with a cor-
responding count of edges contained. For subnetworks containing indirect
connections, the count of term nodes and original gene-term edges is given.
The converted edges column shows the total count of direct connections after
converting any term nodes to gene-gene edges. In each case where indirect
edges were removed, the resulting converted subnetwork was considerably
more dense.
4.2 Quantifying Meta-Paths
One challenge lies in quantifying the meta-paths within a heterogeneous net-
work while giving equal emphasis to each homogeneous subnetwork. Sub-
networks may be sparse or dense and may contain multiple edges between
gene pairs, and edges may be weighted to indicate confidence or else simply
represent the binary presence of a relationship. GeneSet MAPR approaches
this issue by describing each subnetwork as a normalized adjacency matrix,
and each meta-path as a probabilistic transition matrix.
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Adjacency matrix An adjacency matrix is defined as a square matrix
describing the potential connections between every possible pair of nodes in
a network [14]. MAPR creates an adjacency matrix At for every subnet-
work, specified as the homogeneous network containing all edges of type t.
Traditionally, an entry will have a value of 1 if node i shares a connecting
edge e with node j, and 0 otherwise. MAPR modifies this definition (4.1)
to account for networks where genes may share multiple edges, and edges
may have weights indicating the strength or confidence of that relationship.
Values are normalized to the range [0, 1] to facilitate comparison between
disparate network types (4.2). Additionally, each edge is treated as undi-
rected, where the presence of a relationship from i to j implies a mutual
corresponding relationship from j to i. Thus an adjacency matrix for a given
edge type is symmetric.
A˜t ← a˜tij =
∑
etij (4.1)
At =
A˜t
max(A˜t)
(4.2)
Transition matrix If one considers starting at a given node and taking
a single step along any of its connecting edges, then a transition matrix
describes the probability of transitioning from any row node i to any column
node j. Each entry is a non-negative value, and every row and/or column
must sum to 1 [23].
MAPR first finds a meta-path adjacency matrix B˜m by multiplying nor-
malized edge adjacency matrices At in the order specified by the meta-path
m (4.3), such as m = (t1, t2, t3). Each entry in B˜
m describes the number of
paths from node i to j that follow the order of edge types specified by meta-
path m. Prior to each matrix multiplication, values in the main diagonals
are set to 0, so as to omit the influence of loops, where a path encounters a
given node more than once. MAPR avoids the consideration of loops because
any connection from node i to j containing a loop may be more succinctly
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described by the shorter path omitting said loop.
B˜m ← b˜mij =

a
m[0]
ij if i 6= j, len(m) = 1
b˜
(m[0],...,m[n−1])
i · am[n]j if i 6= j, len(m) > 1
0 if i = j, ∀ len(m)
(4.3)
A final meta-path transition matrix Bm is calculated from the meta-path
adjacency matrix B˜m by converting each row into a probabilistic value (4.4).
Note that the transition matrix is directed and asymmetric: it indicates the
probability of transitioning from node i to j along meta-path m, where m
specifies an ordered list of edge types.
Bm ← bmij =
b˜mij∑
k b˜
m
ik
(4.4)
Thus, for each meta-path one wishes to consider, a pre-computed matrix
is stored containing the likelihood of transitioning along said meta-path from
node i to node j, where each node represents a single gene.
4.3 Gene Set Connectedness
Gene sets are often presented as complete, unambiguous sets, where member-
ship of individual genes is binary, as opposed to probabilistic or confidence-
based. Therefore GeneSet MAPR seeks to rank individual genes’ similarity
to the set as a whole. That is, pairwise gene-gene transition probabilities
are aggregated over the input set in order to create a comparable measure
of connectedness. (Section 4.4 introduces consideration for set membership
ambiguity.)
Connectedness The MAPR concept of connectedness is defined along a
given meta-path by taking the union of the likelihood of a gene connecting
to the input set along either the given meta-path m or its inverse m−1 (4.5).
Note that each edge in the network is considered to represent a mutual,
shared relationship, and is therefore undirected. So too are meta-paths in
this context considered to be undirected, where m = (t1, t2) is the same as
m−1 = (t2, t1). A connecting path from the node representing gene g2 to g1
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along m−1 merely represents the reciprocal relationship to that connecting
g1 to g2 along m.
C˜m ← c˜mg =

∑
i∈G b
m
gi +
∑
i∈G b
m
ig
−∑i∈G bmig∑i∈G bmgi if m−1 6= m∑
i∈S b
m
gi if m
−1 = m
(4.5)
The standard score, also known as the z-score, describes for a normal
distribution how many standard deviations σ a particular value is above or
below the mean µ [24]. MAPR takes the standard score over the vector
C˜m, adjusting each raw value c˜mg into a standardized value c
m
g . The result
is a value describing, relative to the typical number of connections along a
specific meta-path, how much more or less connected each gene is to the
input set. These column vectors are horizontally concatenated into a feature
matrix X, where each row describes an individual gene’s relative pattern of
connectedness to the input set (4.7).
Cm ← cmg =
c˜mg − µmc˜
σmc˜
(4.6)
X = [Cm0 , Cm1 , . . . , Cmn ] (4.7)
The final result is a set of features that consider the heterogeneous nature
of the network at an abstract level. The abstraction helps reduce some of the
noise inherent in large, curated networks. MAPR is then able to compare
the pattern of connectedness for individual genes against those already in the
input gene set.
4.4 Gene Similarity Ranking
The gene similarity ranking provided by GeneSet MAPR must be robust:
there may be uncertainty in the input set, and typically around 50-100 times
as many genes excluded as included. Additionally, a primary goal is to move
past the purely statistical view of the gene set — to identify genes related
through their interactions to the set that may have failed to register a notable
measured value in a given experiment. After defining the connectedness fea-
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ture, MAPR’s approach is to learn what uniquely defines the set by applying
an ensemble of regression-based models combined with random sampling.
Ensemble Learning The goal of ensemble learning is to test multiple
disparate hypotheses through the introduction of independent classifiers, or
models, each of which casts a vote based on its own independently learned
prediction [25]. Provided each model performs at least slightly better than
random, then the ensemble, utilizing an appropriate mechanism to aggregate
each model’s vote, should perform better than any typical single model.
GeneSet MAPR trains an ensemble of models to overcome the noise inher-
ent in the input set and the imbalance of the set size versus the number of
unlabeled genes. A supposition here is that there exist many clusters within
the genome with their own patterns of connectedness, and therefore a single
model may work well on one cluster but poorly on others. The number of
models MAPR trains can be set by the user; each additional regression-based
model contributes to the stability of the final gene similarity ranking while
extending the time required by a second or two. Unless otherwise specified,
the number of models in the ensemble was fixed at 31 for the experiments in
this paper.
Each model requires a positive and negative training set, along with a
corresponding label. Labels are defined by an indicator function I, where a
gene g is labeled with the value 1 if it is in the input set G, and 0 otherwise
(4.8). The complete input set G is introduced as the positive training set
x{+} (4.9). A negative training set x{−}i of equal size is created by randomly
sampling from the remaining, unlabeled genes (4.10). The vector of training
labels Y {i} is provided by the indicator function (4.11).
Ig∈G =
1 if g ∈ G0 else (4.8)
x{+} = {g, ∀g if Ig∈G = 1} (4.9)
x
{−}
i = rand ( {g, ∀g if Ig∈G = 0} ) , |x{−}i | = |x{+}| (4.10)
y{i}g = (Ig∈G, ∀g ∈ x{+} ∪ x{−}i ) (4.11)
If, however, the trained model performs no better than random on the
task of differentiating the positive and negative training sets, then x{+} is
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randomly sub-sampled, keeping 75% of the genes in the current set, and a
new x
{−}
i is created. For a single model this may be repeated several times,
until a subset is found that is separable by the model. For example, this may
occur when an input set’s overall pattern of connectedness is not uniquely
discernible from that of the network of a whole, but which may contain two or
more clusters with their own unique profiles. In practice, this has occurred
rarely. The measure used to judge the model’s performance is discussed
below.
LASSO Least Absolute Shrinkage and Selection Operator (LASSO) can
be interpreted as a linear regression model where values in the feature coeffi-
cients vector β{i} are subject to thresholding of the L1 norm (4.12) [26]. This
regularization, adjusted according to the parameter λ, simplifies the learned
model by forcing statistically redundant features to be given a weight of zero.
Coefficients learned from the training data are then used to create predicted
labels Ŷ {i} for every gene in the network (4.13). Note that in this case each
label is a continuous value akin to similarity rather than binary class predic-
tion.
β{i} = arg min
β
1
2N
∥∥Y {i} −X{i}β∥∥2
2
+ λ ‖β‖1 (4.12)
Ŷ {i} =
[
yˆ{i}g0 , yˆ
{i}
g1
, yˆ{i}g2 , . . .
]T
= Xβ{i} (4.13)
For each LASSO model in the ensemble, GeneSet MAPR assigns a model
performance score indicating how closely the predicted labels output by the
model match those that were used to train it. That is, how well can the
model separate its own training data. For this, MAPR uses the coefficient of
determination, or r2 [27]. In the numerator, r2 compares the training label
yg for each gene to its predicted label yˆ
{i}
g . In the denominator, the training
label is compared to the mean of the training labels µ
{i}
Y . Thus, if every item
is labeled correctly by the model, the fraction will approach 0 and the r2
score will approach 1. An r2 score of 0 indicates the model performed no
better than merely assigning every item the mean value, and a negative score
indicates the model failed. A score of 0 or less results in attempting a new
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model based on a random sub-sample of the positive training set.
r2,{i} = 1−
∑(
yg − yˆ{i}g
)2
∑(
yg − µ{i}Y
)2 , r2,{i} ∈ (−∞, 1.0] (4.14)
Once all the LASSO models have been trained, their predicted labels are
collected. As there is no guarantee that the label values for one model are
in a similar range as another, the values are standardized prior to being
aggregated into a final gene similarity score sg (4.15). This emphasizes the
relative value of a label according to each model. Labels are weighted by the
respective model’s r2 score, such that more weight is given to models which
better separate the training data.
S ← sg = 1∑
i r
2,{i}
∑
i
r2,{i}
(
yˆ
{i}
g − µ{i}yˆ
)
σ
{i}
yˆ
 (4.15)
Similarly, feature coefficients are aggregated from each model. In this case,
the sign of the coefficient is important. The sign indicates whether the set
was positively or negatively enriched for a given meta-path, that is, whether
or not the input set had more connections via that meta-path than did a
random sampling of the unlabeled genes. For example, it is more intuitive
to show that set G displayed unusually high connectedness along m1, as
compared to other random sets, than it is to show that connectedness along
m1 was greater than along m2, even though both may be less pronounced
within G than for other random sets. To preserve the sign, feature coefficients
are normalized according to the absolute maximum for that model prior to
weighting by r2 (4.16).
βf =
1∑
i r
2,{i}
∑
i
(
r2,{i}
β
{i}
f
max(|β{i}f |)
)
(4.16)
Thus, GeneSet MAPR returns two ranked lists in relation to the input
gene set. The gene similarity rank orders all genes in the underlying network
by their connectedness to the set. The feature importance list orders the
meta-paths by how useful they were in uniquely describing the set.
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4.5 Implementation Details
Several implementation details are worth noting. Note that computing every
meta-path of length L or shorter in a network containing G gene nodes and
N unique subnetworks will require computation time and storage on the
order of O(NL · G2). This suggests a trade-off between the granularity of
more subnetworks and the maximum depth of considered meta-paths. In
the case of the bioinformatics domain, we chose to limit the meta-paths to
a maximum length of 3 edges. The primary motivation for this decision was
the desire for interpretable features: it was felt there would be little intuition
for connecting paths of length 4 or greater. This consideration may change
for another domain.
Additionally, as discussed in Section 4.3, not all meta-paths need be calcu-
lated. As the edges are undirected, a connection from node i to j along meta-
path (t1, t2, t3) is the same as from node j to i along meta-path (t3, t2, t1).
Omitting these inverse meta-paths reduces the number of computed meta-
paths by 43% (from 1,331 to 803) for the network used here, consisting of 11
edge types and paths up to length 3. This savings asymptotically approaches
50% as N and/or L increase.
Another observation was that the raw count of meta-path connections
was less important than the relative counts, as compared from one node
to another. Hence, what matters in the adjacency matrices are the values
relative to each other, as opposed to the scale of the values. So while the
raw counts are calculated in memory as a floating point value, the matrices
are scaled and converted to 16-bit unsigned integers prior to being stored.
The result is a reduction in required hard drive space with no noticeable
change in the algorithm’s performance. There are likely many opportunities
for compression and optimization that have not yet been explored.
It should be noted that, for a related reason, the normalization applied
in Section 4.1 was removed from GeneSet MAPR’s final implementation. In
practice, the conversion of indirect to direct connections occurs concurrently
with the construction of the adjacency matrix in Section 4.2. If two genes
share multiple edges — multiple shared annotations — then the weights
of these edges are summed during matrix creation, and the final matrix is
normalized. As this is merely a matter of applying division to scale edge
weights, normalizing twice is redundant. The resulting adjacency matrix no
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longer represents a raw count of connecting edges, but rather the overall
strength of all connections within a subnetwork between each pair of nodes.
Other considerations for reducing computational burdens appear in Chap-
ter 7.
4.6 Source Code
All code used to run GeneSet MAPR as well as create the figures in this the-
sis are available in the GitHub repository glinkowski/GeneSet MAPR (URL
below). Example input and output files are also provided.
https : // github . com/ g l inkowsk i /GeneSet MAPR
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CHAPTER 5
EVALUATION OF GENESET MAPR
Given a new tool, we must show how it performs. To that end, GeneSet
MAPR was tested over a wide collection of gene sets against other state-
of-the-art tools and methods. Several aspects of MAPR were evaluated,
including how well it extracts uniquely identifying information for a gene
set, its ability to aid in understanding enrichment, the effect of meta-path
analysis on these tasks, and to what extent it is affected by biases in the
network.
To address the first point — performance of GeneSet MAPR’s Gene Sim-
ilarity Ranking — we measured set membership prediction using area under
the curve (Section 5.1) against another state-of-the-art method, (Section 5.4).
The influence of meta-paths — implicit in comparisons against DRaWR —
is made explicit in Section 5.3. The ability of MAPR to overcome network
quirks is addressed in Sections 5.8 and 5.5. Other evaluations of interest also
appear in this chapter.
5.1 Evaluation Metric: Set Membership Prediction
Evaluating the Gene Similarity Ranking output by GeneSet MAPR requires
two things: a large number of gene sets, and an evaluation metric. The gene
sets collected and tested over the course of MAPR’s development are outlined
in Section 5.2. Of course, there is no ground truth in measuring how similar
one gene is to another; this is clear just from observing the wide variety of
approaches used by the subnetworks in Chapter 3. However, we hypothesize
that if a method is able to successfully identify characteristics unique to a
set, then if some members of the set are hidden during training, they should
still be recognized as highly similar.
The first step is to apply cross-validation. In all of our comparisons of
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gene set similarity, we apply four-fold cross-validation, where one quarter of
the gene set is concealed at a time. That is, the input set is divided into
four equal sections. For each run of the method, three folds are combined
and used as the input set, while the fourth fold is concealed and treated as
unlabeled, along with the rest of the genome. The final version of GeneSet
MAPR allows an end-user to specify the desired number of folds.
Each run of a method then outputs a list of all genes ranked by similarity.
In this list, we compare how highly genes in the hidden fold were ranked,
relative to the rest of the unlabeled data. We measure these results using
Area Under the Receiver-Operating Characteristic Curve (AUC), which com-
pares the true positive rate to the false positive rate [28]. That is, the AUC
measures the area under a curve plotted in a 1 × 1 square where the y-axis
shows how many true members of the hidden set were found and the x-axis
shows how many genes outside the hidden set were falsely labeled as belong-
ing to it. A line following the main diagonal from (0, 0) to (1, 1) represents
the result one would expect from random selection. That is, an AUC less
than 0.5 indicates the method performs no better than random. And AUC
of 1.0 indicates perfect performance, where all hidden genes were labeled as
more similar than any of the remaining unlabeled genes. The AUC reported
for a single gene set is the mean over the four folds. While there is an ar-
gument to be made for emphasizing the Precision-Recall (PR) curve over
ROC, ROC is used in many of the studies cited in this thesis and was kept
for comparability. We hope in the future to incorporate the PR curve into
our evaluations.
As shorthand, this process of predicting the relative similarity of genes
removed from the original input set will be called set membership prediction.
Two assumptions underlie this task: (1) There exists some set of underlying
characteristics than can uniquely describe how members of the input set are
interrelated. (2) The a priori data in the collected subnetworks is able to
represent those characteristics.
5.2 Input Gene Sets: Collection Details
As mentioned, one of the primary evaluations of GeneSet MAPR involved
comparing set membership prediction against other methods. For this we
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Table 5.1: Gene Set Collections
Collection Number
of Sets
Min
Size
Max
Size
Source
MSigDB 53 120 1, 513 Molecular Signatures Database [29]
dbGaP 51 69 447 database of Genotypes and Pheno-
types
[30]
Achilles 75 76 541 Achilles Genetic Fitness [31]
Allen Brain 40 290 336 Allen Brain Atlas Signature [32]
Enrichr Path 40 101 802 Enrichr Pathway [33]
Enrichr Pheno 40 100 1, 706 Enrichr Phenotype Signature [33]
ESCAPE 40 120 1, 925 Embryonic Stem Cell Atlas from
Pluripotency Evidence
[34]
GeneSigDB 40 101 1, 606 Gene Signature Database [35]
GEO 40 141 1, 352 Gene Expression Omnibus [36]
LINCS DN 40 100 228 Library of Integrated Network-
based Cellular Signatures
[37]
Pathcom 40 100 1, 493 Pathway Commons [38]
Reactome 40 101 804 Reactome Pathway Knowledge-
base
[39]
TargetScan 40 101 518 TargetScanHuman [40]
GO (test) 40 103 1, 291 Gene Ontology annotations [15]
assembled several collections of gene sets, each emphasizing a slightly differ-
ent focus in content and/or curation methodology. Collection sizes and data
sources can be found in Table 5.1. Three benchmark collections consisting
overall of 179 individual gene sets were carefully assembled from established
publicly available sources. These were used to test GeneSet MAPR over the
course of development and then to evaluate its performance against other
methods. Later, to ensure MAPR was not over-fitting the benchmark col-
lections, a further 400 gene sets were compiled into 10 additional collections.
Genes in the evaluation sets are not assigned p-values or any other measure
of statistical significance or confidence; gene set membership is provided as
a binary attribute.
Many of the higher-level evaluations were performed across both the bench-
mark and supporting sets, ensuring the trends witnessed were not limited to
a small set of samples. As will be seen, trends occurring over the three
benchmark collections are also duplicated across these additional collections.
This gives us confidence that the three benchmark collections are generally
representative of the performance of GeneSet MAPR as a whole. Thus, some
of the more time-consuming in-depth analyses are performed only over the
benchmark sets.
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A complete list of all gene sets can be found in Table A.1.
5.2.1 Three Benchmark Collections
MSigDB
The Molecular Signatures Database (MSigDB) is compiled by the Broad In-
stitute and is composed of several groups. From the chemical and genetic
perturbations subgroup of MSigDB’s C2 collection, a group of gene sets cu-
rated from databases, literature, and domain experts [29], 53 cancer-related
gene sets were selected for evaluation of GeneSet MAPR. The sets were cho-
sen to represent a range of cancer types and contributors. Each set was
identified by a given lab for a specific cancer variant and is composed of
genes whose expression levels showed significant change from one set of pa-
tients to another, such as healthy tissue vs. sick, or treatment responders
vs. non-responders. Each set is comprised of both up- and down-regulated
genes: genes for which the expression level crossed a thresholded difference
relative to the control group. For the evaluations of GeneSet MAPR, the
corresponding UP and DN segments are combined into a single set.
dbGaP
The Database of Genotypes and Phenotypes (dbGaP) is a repository spon-
sored by the National Institutes of Health (NIH). Gene sets relate to various
genetic and phenotypic datasets [30]. After discarding any containing 60 or
fewer genes, 51 publicly available gene sets were randomly selected. The se-
lected sets represent a mix of disease-related phenotypes and other naturally
occurring biological characteristics.
Achilles
Project Achilles, run by the Broad Institute, aims to catalogue gene essen-
tiality across hundreds of cell lines. Each Achilles gene set corresponds to a
single cell line and contains the genes whose genetic knockout impacts the
overall fitness of that cell line [31]. From Achilles, 75 sets containing at least
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70 genes were selected at random for use with GeneSet MAPR. As with
MSigDB, UP and DN segments were combined into a single gene set.
5.2.2 Ten Supporting Collections
As KnowEnG grew, gene sets from many other sources were made available
to the project. Ten supporting collections of gene sets were selected semi-
randomly from these growing databases, with an effort to avoid data that
was already explicitly a part of the network used in this paper. For each of
the ten chosen data sources, 40 gene sets within the size range of 100-2,000
genes were selected at random. This size restriction is meant to represent
the typical scale of a user’s input gene set while ensuring a valid, comparable
AUC value.
For these collections, any sets represented by separate groups of up- and
down-regulated genes are treated as two separate sets. That is, the UP and
DN groups are not combined into a single set as is the case for MSigDB and
Achilles. In fact, this separation is done explicitly for the LINCS collection,
where only the down-regulated portions of gene sets are considered.
Three of these sets appear to be outliers. Both the Enricher Pathways
and Reactome collections scored exceptionally high AUCs, suggesting some
overlap with the data already in the network. For these two collections,
the pathway subnetwork from Kegg was the third- and fourth-best perform-
ing network, respectively, as seen in Figure 5.3. However, both collections
showed improved performance across most subnetworks, as compared against
the remaining collections. Meanwhile, the other outlier is the collection of
sets derived from Allen Brain Atlas, whose connections appear to be under-
represented within the network. The Allen Brain collection is somewhat
unique from the rest in that it attempts to map gene expression across the
human brain.
5.2.3 One Sanity Check
Finally, one collection of gene sets was created with the explicit intention to
overlap with data already in the network. For this test collection, 40 gene
sets were created from the same GO terms that were used to create the GO
35
Table 5.2: Comparison of Methods by AUC Value
Collection LASSO
ensemble
DRaWR GeneSet
MAPR
MSigDB 0.695 0.684 0.758
dbGaP 0.593 0.622 0.677
Achilles 0.645 0.612 0.714
Allen Brain 0.528 0.578 0.644
Enrichr Path 0.951 0.960 0.966
Enrichr Pheno 0.737 0.774 0.806
ESCAPE 0.637 0.675 0.739
GeneSigDB 0.717 0.691 0.769
GEO 0.666 0.688 0.744
LINCS DN 0.705 0.642 0.745
Pathcom 0.684 0.679 0.756
Reactome 0.933 0.984 0.960
TargetScan 0.702 0.664 0.753
GO (test) 0.971 0.945 0.952
mean 0.726 0.729 0.785
subnetworks. These sets were not meant to gauge the overall performance
of GeneSet MAPR; they were expected to perform well under the set mem-
bership prediction evaluation. Indeed, in Figure 5.3 it can be seen that they
largely performed as expected. They also showed an unusually high util-
ity for the genetic interaction subnetwork, an interesting aside which is less
relevant to this paper than to those assembling the networks.
5.3 Comparison to Non-Network Approach
To tease out the effect of network structure on set membership prediction, we
first compare GeneSet MAPR to an approach we will call LASSO ensemble.
The LASSO ensemble approach applies the same standardization, sampling,
and multiple regression voting as MAPR, but does not compute meta-path
connectedness and otherwise ignores the network structure. Instead, LASSO
ensemble constructs feature vectors where each individual node in the net-
work — gene or annotation term — is treated as an unabstracted feature.
If a gene is annotated by a given term, the value in that entry is set to the
weight of the connecting edge, otherwise it remains zero. If a gene shares
one or more edges with another gene, the sum of those edges is placed into
that entry. Thus, each gene is represented by a sparse vector of over 40,000
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individual features. In order to treat each subnetwork with equal empha-
sis, the weight of each edge in that subnetwork is divided by the sum of
all weights, such that the total sum of all edge weights in a subnetwork is
equal to 1. Thus, if one subnetwork contains many more edges than another,
the weight of each individual edge is less for the denser subnetwork. The
non-negative values of this feature vector are calculated from the same sub-
networks used by the full MAPR method, and indicate the strength of the
relationship between a gene and any other node on a one-to-one basis. In
terms of the network, this approach considers every individual edge, rather
than the pattern of occurrence of multi-length paths.
Despite utilizing the same raw data, the LASSO ensemble approach sig-
nificantly underperformed the full GeneSet MAPR. Looking at the mean
AUC over each gene set collection in Table 5.2, MAPR showed an average
improvement over LASSO ensemble of 9.2%. Considering only the three
benchmark collections — MSigDB, dbGaP, and Achilles — LASSO ensem-
ble ranked 45%, 2%, and 15% of the sets in each respective collection with an
AUC at or above 0.7. Meanwhile, MAPR ranked 85%, 22%, and 69% at 0.7
or better, respectively. These results suggest that the abstracted meta-path
features, which consider network structure, are better at recovering gene set
membership than specific observations on individual genes. It is likely that
the meta-path features reduce the likelihood of over-fitting a model to noise
in the data. Although the generation of meta-path features in MAPR re-
quires more upfront computation, performing set membership prediction on
the reduced number of high-level features makes the models more efficient
and robust.
5.4 Comparison to DRaWR
Next, GeneSet MAPR’s gene similarity ranking is compared to that which is
output by Discriminative Random Walk with Restart (DRaWR), a state-of-
the-art approach that has been shown to be effective in this context [41]. Like
MAPR, DRaWR explicitly uses the network structure to define similarity of
individual genes to an input set. Unlike MAPR, it does so without distin-
guishing between edge types, combining any heterogeneous subnetworks into
a single homogeneous network.
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5.4.1 Discriminative Random Walk with Restart
In a network, a random walk is a walk wherein at each node, the next edge in
the walk is chosen at random from any of the edges shared by that node. A
similarity measure can then be defined as the probability, if a random walk
was initiated at a given source node, that the walk would terminate at any
other specified node. A restart probability can be added to the metric, indi-
cating the rate at which the walk will randomly be terminated and restarted
from the source node. A higher restart rate, then, emphasizes shorter walks.
DRaWR applies the random walk approach, using the full input gene set as
source nodes. The entire network is formed into a matrix, including non-gene
terms, and the restart rate is an adjustable parameter. When subnetworks
are combined, they are equalized by dividing each edge weight by the total
sum of edge weights for the subnetwork. Weights are then summed across
subnetworks, and compiled into one homogeneous network. The network
matrix is multiplied by a weight vector until convergence. This is a key
difference with MAPR, which specifically distinguishes the different meta-
path types, quantifies connectedness for each separately, and then learns and
uses the most relevant meta-paths to calculate the final ranking.
DRaWR was run by combining the eleven subnetworks from KnowEnG
and setting the restart probability to 0.3. DRaWR was also tested with a
restart set to 0.5, but this did not perform as well and is not presented here.
5.4.2 Results
MAPR achieved a higher average AUC per collection than DRaWR across
all tested collections except Reactome, as seen in Table 5.2. In Figure 5.1,
it can be seen that GeneSet MAPR performs well (AUC ≥ 0.7) on a higher
percentage of sets from each collection than DRaWR. Specifically, MAPR
performs well on 22, 10, and 50 more sets than DRaWR in MSigDB, dbGaP,
and Achilles, respectively. The scatterplots of Figure 5.2 show the AUCs of
individual sets, with the results from MAPR along the y-axis and DRaWR
along the x-axis, where a dot along the main diagonal y = x indicates the
set acheived the same AUC using both methods. As shown in the figure,
MAPR improved the AUC over DRaWR for 96%, 88%, and 100% of sets in
MSigDB, dbGaP, and Achilles.
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(a) MSigDB (b) dbGaP
(c) Achilles
Figure 5.1: Comparison showing proportion of AUC scores for all sets
across a collection. Plot shows the percentage of sets along the x-axis that
achieved the AUC along the y-axis or better.
Although both methods rely on the same underlying subnetworks, the
overall improvement of MAPR over DRaWR is likely due in large part to the
consideration of the heterogeneous nature of the network through the use of
meta-paths. Comparing all three methods (Figure 5.1) we see no improve-
ment across MSigDB for considering the network structure in DRaWR versus
LASSO ensemble, but notable improvement with the addition of the meta-
path based features of MAPR. This is different from the dbGaP collection,
where improvement can be attributed to the network structure (DRaWR
vs. LASSO ensemble), with an additional boost due to the meta-path ap-
proach of MAPR. Additionally, as is apparent in Figure 5.2, there is some
positive correlation between the DRaWR and MAPR AUCs, with a Pearson
correlation of 0.80, 0.32, and 0.58 for MSigDB, dbGaP, and Achilles. This
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(a) MSigDB (b) dbGaP
(c) Achilles
Figure 5.2: Scatterplot of AUC scores for individual sets in each benchmark
collection. X-axis represents the AUC received using DRaWR and y-axis
the AUC from GeneSet MAPR. Sets along the diagonal received the same
AUC for both methods, while those above performed better when using
MAPR.
suggests that the connectedness of some gene sets is inherently higher than
others when using the set of subnetworks on which DRaWR and MAPR were
tested.
5.5 Effect of Individual Subnetworks
One idea we wished to explore was the effect of individual subnetworks on the
performance of GeneSet MAPR. For each gene set, MAPR was run using only
meta-paths created from a single homogeneous subnetwork at a time. Meta-
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Figure 5.3: Comparison of mean AUC values over a collection for each
subnetwork. The color range from red to green indicates the range of mean
AUC values relative to that specific collection, from low to high. The total
count of all edges in the network appear in the right-most column.
Subnetworks are sorted by mean AUC over all collections.
paths of length one, two, and three were all still considered, but the edge
type was the same at each step in the path. In Figure 5.3, the subnetworks
are sorted by their average AUC across each collection. As can be seen, the
full heterogeneous network outperforms any single homogeneous subnetwork
across every collection. That is, MAPR successfully combines useful data
from the assembled subnetworks such that the whole works better than its
individual parts. Figure 5.4 shows a more visual representation of the relative
results over the three benchmark collections, where it can be seen that some
subnetworks had a much wider range of values than others for individual
gene sets, and some subnetworks consistently outperformed others.
A few other trends are observable. The biological processes subnetwork
is almost universally the best-performing subnetwork for each collection,
while coexpression and genetic interaction are almost universally the worst-
performing. As can be seen, however, coexpression and genetic interaction
are incredibly sparse in this version of KnowEnG. In a network of over 23
thousand genes, there are over 500 million possible gene-gene pairs, and a
subnetwork of a few thousand edges has very few opportunities to provide a
meaningful signal to the model. On the other hand, the direct interaction
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Figure 5.4: Bar graph shows mean AUC over a collection for subnetworks
indicated in legend. The overlaid box plot shows the range for the upper
and lower quartiles of all considered sets, with a horizontal line within
showing the median. The whiskers extend from the median to include the
farthest datum within a range of 1.5 times that of the the quartile.
subnetwork performs admirably for how sparse it is, with a typical AUC of
0.67 across each collection. It is reasonable to expect a dense network to per-
form better than a sparse one; however, the relationship between the typical
collection AUC and the number of edges in a subnetwork is only moder-
ately positive, with a Pearson correlation coefficient of 0.39. Here, MAPR’s
approach of standardizing meta-path counts relative to the expectation is
able to compensate for varying edge density, putting more emphasis on the
content and methodology of the subnetworks.
One surprising result was the performance of the textmining subnetwork.
Textmining was often one of the best subnetworks across a collection, despite
its relatively small number of edges and unorthodox premise. A clue may
lie in how well it performed on the final test collection, the GO annotations.
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Naturally, the GO collection received high AUCs with the GO subnetworks,
but here textmining also performed quite well, suggesting there may be some
overlap in the information conveyed by the GO subnetworks and textmining.
5.6 Meta-Path Rankings across Gene Set Collections
Similar to the effect of individual subnetworks, we can examine the utility of
specific meta-paths within the network. Here, we examine the most useful
meta-paths across the three main curated gene set collections. Specifically,
this evaluation considers what percentage of sets within a collection used a
given meta-path as one of the top five most uniquely identifying meta-paths.
That is, we count how often a meta-path was given one of the five highest
weights by GeneSet MAPR’s feature importance list.
Tables 5.3, 5.4, and 5.5 show the ten meta-paths occurring most frequently
in the top five for the MSigDB, dbGaP, and Achilles collections, respectively,
along with the mean feature weight across the collection. For MSigDB, the
majority of sets highly weighted a homogeneous textmining meta-path, and
nearly half a homogeneous biological processes GO meta-path. This is unsur-
prising, as these two subnetworks were the best-performing subnetworks for
MSigDB, as seen in Section 5.5. However, in contrast to the other two collec-
tions, sets across MSigDB are dominated by a few highly weighted features
as seen by the high average feature weight and top-5 occurrence in Table 5.3.
The top meta-paths for dbGaP and Achilles have lower rates of occurrence,
indicating a more even distribution of selected meta-paths across the collec-
tions. In general, cellular component, biological processes, and textmining
were very useful subnetworks and occur in various combinations with other
edge types in the meta-paths for all three collections. However, whereas
sets in dbGaP tend to use textmining in combination with other edge types,
Achilles favored combinations utilizing GO, including an edge type omitted
by the other two: molecular function. So while there is some similarity in
the feature profile over a collection — with MSigDB appearing particularly
homogeneous — there is variety in the meta-paths favored by each.
One further observation is the variation in meta-path length. While the
thirty features presented in these three tables include fourteen length-3 meta-
paths, the most frequently used paths are the shortest. Longer paths appear
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Table 5.3: Important Meta-Paths for MSigDB
Weight in Top-5 Meta-Path Length
0.385 58.5 % STRING textmining-STRING textmining 2
0.311 45.3 % GO BioProc 1
0.236 37.7 % GO CelComp 1
0.219 37.7 % STRING textmining-STRING textmining-
STRING textmining
3
0.212 35.8 % GO BioProc-GO CelComp 2
0.157 20.8 % STRING textmining 1
0.173 18.9 % STRING textmining-blastp homology-
STRING textmining
3
0.148 15.1 % PPI physical association-PPI physical association 2
0.098 13.2 % pfam domain-GO BioProc-pfam domain 3
0.116 11.3 % pfam domain-STRING textmining-pfam domain 3
Table 5.4: Important Meta-Paths for dbGaP
Weight in Top-5 Meta-Path Length
0.132 27.5 % GO BioProc 1
0.121 21.6 % GO CelComp 1
0.113 19.6 % STRING textmining 1
0.105 15.7 % GO BioProc-GO BioProc 2
0.087 15.7 % STRING textmining-STRING textmining 2
0.113 13.7 % STRING textmining-pfam domain-STRING textmining 3
0.095 13.7 % STRING textmining-STRING textmining-
STRING textmining
3
0.092 13.7 % blastp homology-STRING textmining-blastp homology 3
0.064 13.7 % STRING textmining-GO BioProc-STRING textmining 3
0.082 11.8 % blastp homology-PPI direct interaction-blastp homology 3
Table 5.5: Important Meta-Paths for Achilles
Weight in Top-5 Meta-Path Length
0.177 34.0 % GO BioProc 1
0.165 30.2 % GO BioProc-GO CelComp 2
0.123 22.6 % GO CelComp 1
0.110 17.0 % GO BioProc-GO BioProc-GO CelComp 3
0.091 17.0 % GO BioProc-PPI genetic interaction-GO BioProc 3
0.090 17.0 % blastp homology 1
0.068 11.3 % GO BioProc-GO BioProc 2
0.062 11.3 % GO MolFunc-GO CelComp-GO MolFunc 3
0.061 11.3 % GO MolFunc-PPI genetic interaction-GO MolFunc 3
0.061 11.3 % GO MolFunc-PPI physical association-
PPI physical association
3
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to play more of a supporting role in the models. At the same time, there
is a greater number of longer meta-paths, with subtler variety. It may be
that there is little difference in a model choosing to weight the meta-path
mi = (Ho, Bp, Ho) over mj = (Ho, Tm, Ho) or mk = (Bp, Ho, Ho). An
evaluation focusing explicitly on path length appears in Section 5.7, and
thoughts about selecting the most representative meta-path from a group
appear in Chapter 7.
5.7 Consideration of Meta-Path Length
Table 5.6: Effect of Meta-Path Length on AUC Value
Collection only
Len=1
only
Len=2
only
Len=3
Len=1 or
Len=2
all
Lengths
MSigDB 0.731 0.749 0.751 0.752 0.758
dbGaP 0.671 0.672 0.661 0.674 0.677
Achilles 0.696 0.716 0.712 0.716 0.714
Allen Brain 0.643 0.642 0.640 0.646 0.644
Enrichr Path 0.959 0.964 0.955 0.967 0.966
Enrichr Pheno 0.794 0.799 0.788 0.806 0.806
ESCAPE 0.723 0.734 0.731 0.737 0.739
GeneSigDB 0.748 0.766 0.762 0.770 0.769
GEO 0.728 0.739 0.735 0.743 0.744
LINCS DN 0.715 0.747 0.741 0.748 0.745
Pathcom 0.734 0.752 0.751 0.753 0.756
Reactome 0.959 0.950 0.947 0.959 0.960
TargetScan 0.723 0.746 0.746 0.748 0.753
GO (test) 0.950 0.935 0.923 0.951 0.954
mean 0.770 0.779 0.775 0.784 0.785
Another aspect of GeneSet MAPR we wished to understand was the effect
of path length. The longer a path, the less intuitive sense it is likely to
offer. So to better understand the effect of path length, MAPR was run
over all gene sets with varying restrictions on path length. The approach
used in the above evaluations considered meta-paths with a length of up to
3 edges. MAPR was then run where it was restricted to using meta-paths
of length 1. Two additional runs were performed, using length 2 and length
3, respectively. Finally, a run was performed allowing a mixture of lengths 1
and 2, but nothing longer.
As seen in Table 5.6, using meta-paths of only length 1 resulted in the
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(a) size: 630; AUC: 0.853 (b) size: 226; AUC: 0.657
(c) size: 336; AUC: 0.849 (d) size: 165; AUC: 0.690
Figure 5.5: Plots show proportion of nodes with degree of X or less for an
input set and the corresponding top N genes returned by GeneSet MAPR.
The x-axis is presented in log scale to account for the scale-free nature of
the network.
lowest average collection AUC. Meta-paths of length 2 performed better than
length 1, and the combination of lengths 1 and 2 resulted in yet another boost
in performance. However, the addition of length 3 meta-paths resulted in a
flat or very modest improvement for most collections, and in some cases a
slight decrease.
It appears that increasing the meta-path length has diminishing returns.
As discussed earlier, separating the gene ontology subnetwork into three sep-
arate subnetworks improved performance. This suggests that, in striking a
balance between variety of edge types and length of meta-paths, there may
be more to gain from either adding additional subnetworks or logically sep-
arating large ones than merely adding longer meta-paths.
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5.8 Distribution of Node Degree in Results
As mentioned in Chapter 3, the scale-free nature of biological networks poses
a challenge when attempting to define similarity. GeneSet MAPR employs
two steps to mitigate this issue, as outlined in Chapter 4. First, the transition
matrix adjusts the likelihood of one gene connecting to another according to
the originating gene node’s overall edge count. Second, standardization of
meta-path counts accounts for meta-paths with significantly higher or lower
density. Here, we examine how well MAPR meets this challenge.
Figure 5.5 shows comparisons of four sets: two where the top-ranked genes
output by GeneSet MAPR show a similar distribution of node degree as the
original set, and two where MAPR’s results are skewed towards higher-degree
nodes. These sets were chosen semi-randomly, to represent large and small
sets, with high and low AUCs. Each figure shows the cumulative distribution
of nodes by degree for the full network, the original set, and the top-N ranked
genes from MAPR, where N is the same size as the original set.
Data for all sets evaluated in this chapter can be found in Table A.1. For
every set, the median degree of the original set is compared to the median
degree of the top-N MAPR-ranked genes. In another column, the difference
between the two medians is adjusted to show the change relative to the
median of the original set. As another way of presenting the data, there is
also a comparison of the proportion of genes with a degree greater than 200,
and the change from the original set to MAPR’s top-N. (As mentioned in
Chapter 3, the median node degree in the network is 69.)
Most sets showed some increase from the median degree of gene nodes in
the input set to the median degree in the MAPR top-N. A small proportion
of sets showed a significant increase in median node degree. However, while
the median degree of the input set was related to the AUC achieved by
MAPR, with a Pearson correlation coefficient of 0.64, the amount by which
the median degree changed showed a slightly negative correlation to MAPR
AUC (-0.34). That is, MAPR tended to perform worse on sets where its
results improperly skewed towards higher-degree nodes. Interestingly, set size
shows little correlation with any of the other factors, and only a very weak
negative correlation (-0.12) with set membership prediction AUC. Rather, the
single item that correlates the most with set AUC is the density of edges in the
set. This correlation is only moderate, but it does point to an unfortunate, if
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somewhat obvious, conclusion. The sets for which GeneSet MAPR can best
predict hidden members are those with the most knowledge upon which to
draw, in the form of network connections. (This is true for DRaWR as well,
which used the same KnowEnG network. The correlation between DRaWR
AUC and median node degree for a set was 0.58.) Naturally, the better a
profile that can be created for a set using the underlying network, the more
reliable the results.
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CHAPTER 6
CHARACTERIZATION OF A NOVEL
GENE SET VIA GENESET MAPR
To illustrate the utility of GeneSet MAPR as a gene set characterization tool,
here we report a detailed analysis of a recently developed gene set. The set
comes from the Breast Cancer Genome Guided Therapy Study (BEAUTY)
[42], and was created by examining the differential expression among pa-
tients diagnosed with a form of breast cancer that is particularly resistant to
treatment. MAPR was used to rank genes by similarity to the set — to iden-
tify the interaction neighborhood — and to help characterize the make-up
of the set. Of specific interest are genes ranked highly by MAPR, but which
failed to cross the study’s statistical thresholds, or otherwise went unmen-
tioned. MAPR’s ability to learn the pattern of connectedness within a set
and identify related genes is especially useful here, where hard cutoff values
established by convention are susceptible to noise over a small sample size.
Indeed, sample size was a challenge in the study as a whole, as it is for any
study whose subjects suffer from a rapidly evolving disease. Additionally,
the gene set of interest comes from a subset of the study consisting of only
44 patients. With this sample size and the desired p-value specified at 0.05
or less, the statistical power of this subset is greatly reduced, increasing the
likelihood of a Type II error. A Type II error occurs when an effect should
be witnessed but is not. In this case, a Type II error would result in the
omission of a gene from the set when it should be included — the perfect
opportunity for a tool such as GeneSet MAPR to fill in missing members of
the set.
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6.1 BEAUTY Triple Negative Responders: A New
Gene Set
We were presented with a gene set curated as part of the longitudinal BEAUTY
study performed at the Mayo Clinic [42]. The set consists of genes exhibit-
ing significant differential expression (DE) levels between responders and
non-responders diagnosed with triple negative breast cancer (TNBC), a clin-
ical molecular subtype of breast cancer where tumors are negative for ER
(estrogen receptor), HER2 (epidermal growth factor receptor 2), and PR
(progesterone receptor). This gene set will be referred to as the BTNR set.
BEAUTY consisted of 132 patients with stage I-III breast cancer, with a
tumor at least 1.5 cm in size, who had been recommended for treatment by
neoadjuvant chemotherapy. Surgery was performed following completion of a
targeted drug regimen. Patients experiencing pathological complete response
(pCR) were identified as those who had no invasive tumor in the breast and
axillary lymph nodes. A third of the patients had TNBC and experienced
a pCR rate of 54.5% (24 out of 44), as opposed to the overall rate of 33.3%
(44 out of 132). The log fold change (logFC) in DE of genes in tumor tissue
was measured between pCR and non-pCR TNBC patients. Genes in the set
met two thresholds: p-value 0.05; and the absolute value of logFC 1. The
final BTNR set consisted of 384 genes, of which 323 occur in the KnowEnG
network with at least one connecting edge.
MAPR emphasizes connections to genes which these statistical thresholds
alone could not. One highly ranked group identified in BTNR are claudins,
many of whose members are markers of poor survival in cancer patients, but
who show only subtle changes in DE. Two other groups are kallikreins and
collagen alpha chains. While a few of these genes are part of the BTNR set,
they were not mentioned in the BEAUTY study; MAPRs similarity rank-
ing brought attention to them. Ranking and set membership is contrasted
against a handful of other cancer sets selected from the MSigDB collection.
The rates of single nucleotide variation (SNV) and copy number variation
(CNV) between pCR and non-pCR patients is provided in the BEAUTY
supplemental tables.
Gene mutation rates from The Cancer Genome Atlas (TCGA) are also
examined, drawing on over 30,000 cases. Using TCGAs Genomic Data Com-
mons Data Portal (GDC), the mutation rate is calculated as the percentage
50
of all cases in GDC where the gene was tested for simple somatic muta-
tions that were found to be positive. Additionally, the Catalogue of Somatic
Mutations in Cancer (COSMIC) maintains a cancer gene census, catalogu-
ing genes causally implicated in cancer. Genes in Tier 1 show documented
relevant activity and evidence of mutations that promote oncogenic trans-
formation. Tier 2 genes show strong implications in cancer but with less
evidence, typically indicating more recent targets.
6.2 Set Characterization from MAPR Feature Ranking
Table 6.1: Meta-Path Importance for BTNR
Rank Weight Meta-Path Length
1 0.497 GO CelComp 1
2 0.362 GO BioProc 1
3 0.333 STRING textmining-blastp homology-STRING textmining 3
4 0.308 STRING textmining-kegg pathway-STRING textmining 3
5 0.239 blastp homology-GO MolFunc-blastp homology 3
6 0.228 PPI physical association-PPI physical association 2
7 0.162 GO BioProc-GO BioProc 2
8 0.161 PPI genetic interaction-blastp homology 2
9 0.157 blastp homology-STRING textmining-blastp homology 3
10 0.140 pfam domain 1
11 0.133 blastp homology-GO BioProc-blastp homology 3
12 0.124 pfam domain-PPI genetic interaction-pfam domain 3
13 0.120 PPI physical association-blastp homology 2
The feature ranking output by GeneSet MAPR typically provides around
10-20 positively weighted meta-paths. There is typically a handful of meta-
path features with dominant weights, and a long tail of lower-weighted paths
which may be variations on a given pattern. The higher the number of regres-
sion models specified by the user, the longer the tail of minuscule aggregated
feature weights. Here, we only consider features with a weight of 0.10 or
greater.
Table 6.1 shows the top-ranked meta-paths for BTNR. As can be seen,
the two most dominant meta-paths are the length-1 paths GO CelComp and
GO BioProc. These two meta-paths consider connections through any of the
GO terms in the GO hierarchy that appear under cellular component and
biological processes, respectively. This indicates that the genes in BTNR
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were most connected to each other through shared membership in these two
collections of GO terms.
The next two most important meta-paths contain the STRING Textmining
edge, leveraging shared presence in academic literature. While a shared
textmining edge offers less biological insight, textmining has been one of the
more predictive edges for set membership over the tested gene set collections
as it does indicate a body of evidence exists relating one gene to another.
Along these lines, the high occurrence of blastp homology in these top-ranked
meta-paths indicates that our knowledge of direct functional relationships
between genes in BTNR may be limited, and in this case connections are
facilitated through homologous genes.
6.3 Novel Findings from MAPR Gene Ranking
GeneSet MAPR was applied to rank genes by connectedness to BTNR. Of
specific interest are genes found by MAPR to have high connectedness to the
set, but which failed to meet BTNR’s statistical cutoff values for DE and p-
value. The following three families of genes showed a dramatically increased
representation among MAPR’s top-ranked genes. Data regarding mutations
and presence in other cancer sets can be found in the referenced appendices.
We focus the evaluation of GeneSet MAPR’s ranked gene list on the top 400
genes. This number was chosen somewhat arbitrarily to represent the top-N
genes a researcher may consider worth her time to investigate. In a network
of 23,782 human genes, 400 represents merely the top 1.7%. Additionally,
400 is similar in scale to the original BTNR set (384 genes).
Claudins
Claudins are important to cell adhesion and flow of molecules in the intercel-
lular space. While BTNR contains 6 claudins, MAPR lists 20 with a rank of
400 or better, as seen in Tables B.1 & B.2. Three of these were found by the
BEAUTY study to have a higher rate of SNV or CNV mutation in TNBC
non-responders, yet were not captured by the BTNR set. Claudins show a
low rate of inclusion in the other 9 cancer sets and are not highly ranked by
MAPR for those sets, suggesting a unique relevance to BTNR.
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Claudins have been implicated in the progression of metastasis in various
cancers, as they play a critical role in allowing or blocking cancer cells from
crossing endothelial barriers [43]. Numerous epithelial-derived cancers dis-
play altered claudin expression patterns and certain claudins can now be used
as biomarkers to predict patient prognosis. Changes in claudin expression
patterns have been observed in numerous cancers, and some specific claudins
can be used as biomarkers indicating patient prognosis. Indeed, claudin-
low tumors have been identified as a distinct molecular subtype [44, 45].
This is facilitated by interactions with E-cadherin (CDH1), which was rel-
atively highly ranked by MAPR (rank 494 of 23,782). Interestingly, while
claudin-low tumors tend to display a triple-negative phenotype, very few
triple-negative breast cancers are claudin-low.
Kallikreins
As serine proteases, kallikreins play a role in severing peptide bonds. In
Tables B.3 & B.4, it can be seen that BTNR contains 7 kallikreins and MAPR
lists those plus another 7 in the top 400. Most of BTNR’s 7 kallikreins
are members of the other explored cancer sets, while MAPR’s additional
kallikreins are not. One of these additions, KLK2, is listed as a Tier 1 cancer
gene by COSMIC but was not included in BTNR by BEAUTY.
Kallikreins are cited by many studies as indicators of poor prognosis in
cancer [46], and are often down-regulated in breast cancer patients. In-
deed, many of the kallikrein family were found to have lower expression in
BEAUTY non-responders than in responders. Several kallikreins have been
shown to be useful biomarkers for breast cancer, including KLK3, KLK4,
KLK5, KLK6, KLK8, KLK10, KLK13, and KLK14 [47]. Most of these were
included in BTNR and other cancer sets, and MAPR lists all but KLK3 in
the top 400. However, their presence was not addressed by BEAUTY [42];
MAPR’s gene ranking drew attention to their potential importance.
Collagen Type N Alpha Chains
The BTNR set contains 6 collagens, all of which receive a MAPR ranking of
at least 233, as shown in Tables B.5 & B.6. MAPR ranked an additional 31
in the top 400, most of which have potentially significant levels of mutation
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among cancer patients, according to TCGA. Of these, 3 were observed by
BEAUTY to have a significant difference in rate of SNV and/or CNV muta-
tions between TNBC responders and non-responders, but were not included
in BTNR. COL3A1, at rank 378, is listed as a Tier 2 gene by COSMIC, but
was also not included in the BTNR set. COL1A1, at rank 411, is similarly
listed as a Tier 1 gene, but was not included.
One gene each from the Type II, IV, VI, XXVIII collagen chains, as well as
two from Type IX, were found to be differentially expressed between respon-
ders and non-responders. MAPR ranks many of the alpha-chains highly,
with the Type IV, V, VI, XV, XVII, XXV, XXVII, and XXVIII chains
falling within the top 100, and several others falling within the top 400. Sev-
eral alpha-chains have been linked to cancer progression. Type VI (5 genes
at rank 278 or better) promotes both tumor progression and chemotherapy
resistance, suggesting a feasible anticancer strategy wherein collagen VI is
suppressed [48]. Increased Type V (3 genes at rank 348 or better) has been
found in the desmoplasia surrounding tumors in breast tissue [49], and ev-
idence in mice indicates Type V chains as potential targets for inhibiting
tumor growth [50]. Type X (rank 88) has been identified as a biomarker for
colon cancer, with increased levels indicating the presence of a tumor [51].
Aberrations in Type I and Type III chains have been linked to malignant
tumors via the formation of readily degradable collagen bundles [52]. Both
Type I genes were highly ranked, with COL1A2 (rank 267) showing a notable
difference in mutation rates between pCR and non-pCR TNBC patients. The
Type III collagen COL3A1 (rank 378) showed a significant general rate of
mutation and is listed as a Tier 2 gene by COSMIC. Types XIV (rank 155)
and XXII (rank 59) showed significant rates of mutation among pCR TNBC
patients, as opposed to non-pCR, although neither exhibited the required
DE and p-value to be included in BTNR. Interestingly, Type XI alpha 1
(COL11A1) was ranked highly by MAPR (rank 170), while the remaining
members of type XI were not. COL11A1 has been identified as an accurate
marker for invasive breast carcinoma lesions [53], and as a potential target
for general cancer therapy [54].
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6.4 Enrichment Using MAPR Gene Ranking
One common approach to characterizing a gene set is to examine enrichment
for annotation terms. Put simply, if an annotation term has more mem-
bers in the target gene set, then the set is positively enriched for that term.
Conversely, if the set contains fewer members of the annotation term, then
the term is negatively enriched. Enrichment is not a purely binary concept;
terms can be more or less enriched than others for a set. A popular tool
for comparing enrichment is Gene Set Enrichment Analysis (GSEA), by the
Broad Institute. GSEA compares random permutations of the input phe-
notype or gene set to return a normalized enrichment score (NES) for each
annotation term considered.
In the case where a user has a ranked or otherwise scored list of all genes,
the NES indicates how strongly members of a term are clustered near the
top or bottom, or whether they are evenly distributed. This is compared
against the null hypothesis — what would be expected in a uniform random
distribution — by creating random permutations of the input set.
A ranked list for GSEA was created from BTNR by sorting the 14,228
genes for which BEAUTY had DE values by the magnitude of the fold change.
There occurred 619 ties, which were ordered according to their p-value. The
remaining 9,554 genes for which BEAUTY had no values but occurred in
KnowEnG were tied at the bottom of the list. The MAPR ranked list con-
tained 1,417 ties distributed fairly evenly throughout the 23,782 genes.
6.4.1 Results from GSEA
Using the MAPR ranked list as input, terms were sorted by the NES re-
turned by GSEA, which can be found in Table C.1. Terms consisting of over
500 genes were ignored. Among the top terms, the following functions were
highly represented: membrane / extracellular matrix, ion transport, cell ad-
hesion, and signaling. The top 50 GO terms were selected and entered into
ReviGO to create the visualization in Figure 6.1(a). ReviGO transforms
the data into a lower-dimensional semantic space, enabling some of these
functional clusters to be highlighted visually [55]. For example, a large clus-
ter of transport terms can be seen to the right, and smaller clusters, such
as the transmission/signalling pair, are scattered elsewhere. ReviGO’s own
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functional clustering of the GO terms can be seen in Figure 6.1(b).
Of particular interest are terms ranked highly by GSEA after running
GeneSet MAPR that were not otherwise ranked highly for BTNR or the
other 9 cancer sets — that is, uniquely important terms that were discovered
only after running MAPR. These terms and respective GSEA scores appear in
Table C.1. Of these, terms containing members of the gene families in Section
6.3 were related to protein digestion/absorption (via kallikreins’ effect on
peptide bonds), the extracellular matrix, or membranes. Top-scoring terms
that largely did not contain members of those gene families typically related
to signaling, epidermal growth factor, cell adhesion, or ion transportation
across membranes.
One final question is how much the enrichment scores are influenced by
the families of genes identified in Section 6.3. Put another way, one might
have the reasonable concern that MAPR overfit its model to the input gene
set, identifying a small handful of annotations that are highly enriched for
the set and simply returning genes sharing those annotations. However, the
approach of using meta-paths abstracts away some of these finer details,
reducing the potential to overfit to noisy data. Looking at the top 100 terms
returned by GSEA as positively enriched for the MAPR ranked list in Table
C.1, only 38% contained any genes from the families discussed in Section 6.3.
In fact, no single term accounted for more than 17% of the top 323 MAPR-
ranked genes. So while MAPR’s gene similarity ranking is influenced by the
terms for which a set is enriched, such terms are clearly not the only factor,
as might be expected if the model overfit to the terms in the network.
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(a)
(b)
Figure 6.1: Top shows top-scored GO terms in ReviGO’s
reduced-dimensionality semantic space, where a few functional clusters can
clearly be seen. Bottom shows ReviGO’s interpretation, represented by the
largest term in the group.
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CHAPTER 7
FUTURE WORK
As with any research project, it seems the single most constricting resource is
time. Several topics are outlined here where either an addition was planned,
or an implementation had not undergone proper evaluation. Some interesting
ideas were left aside in order to properly evaluate the core functionality of
GeneSet MAPR. It is the hope of the author that we will have the opportunity
to explore these ideas in the future.
One partially completed evaluation against another method is presented
first. Next, the following potential additions are presented in order of ex-
pected effort to implement, from least to most.
7.1 Comparison to GeneMANIA
It was our intention to provide a comparison to another established state-
of-the-art network-based method for ranking genes by similarity to a set:
GeneMANIA [56]. However, as provided, GeneMANIA utilizes a much dif-
ferent set of underlying networks than was used to evaluate GeneSet MAPR,
instead leveraging over a hundred relatively sparse networks. It is possible
with GeneMANIA’s source code to import our own subnetworks, allowing
for a more direct one-to-one comparison of the methods. Unfortunately, this
is a more drawn-out process that is harder to automate. While initial com-
parisons over a small handful of gene sets was positive, we felt it would be
inappropriate to provide results until we could show trends over a broader
sample size. It should be noted that in [41], DRaWR compared favorably
against GeneMANIA, so we are optimistic.
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7.2 Connectedness as Enrichment
It is reasonable to suppose that GeneSet MAPR’s connectedness could be
used as a stand-in for enrichment. MAPR already finds genes that share
more connections to the input set than would be expected for a random
sample of the same size; it is a trivial manner to apply the same process
to individual annotation terms. Indeed MAPR already outputs a scored list
of enriched terms. To do this, a gene-by-term feature matrix is created, to
which the sampling and regression approach from Section 4.4 is applied. Any
term sharing an edge with a gene in the set is considered, while any term not
connected to the set cannot be scored, and anyway would never be considered
enriched.
The connectedness score from MAPR was compared against normalized
enrichment score from GSEA for several gene sets selected from those with
the highest and lowest AUCs. The exact same annotation terms from the
KnowEnG network were input into GSEA to ensure both methods used the
same data. The correlation between MAPR and GSEA enrichment scores was
surprisingly low. Curiously, GSEA managed to produce positive enrichment
scores for some annotation terms that shared no edges with the input gene
set. Furthermore, the enrichment scores from GSEA over each gene set
were moderately correlated to the size of the annotation terms (typically
∼0.45). This correlation was even stronger when considering only positive
enrichment scores (typically ∼0.76). The connectedness score from MAPR
showed almost no correlation to term size (absolute value less than 0.23).
Here, only immediate length-1 connections were compared, but this process
can readily be generalized to longer paths, essentially unrolling a meta-path
to see what terms facilitate the connections. Connectedness is a logical way
to think about enrichment, and this aspect deserves further investigation.
7.3 Accepting Ranked Sets
Currently, GeneSet MAPR accepts a gene set as a simple list of items without
any ranking or scores. Naturally, a researcher may already have a probabilis-
tic understanding of their gene set, or some other measure by which the set
has been ranked. Implementation of this change would be easy enough. In
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fact, two options exist: weight the contribution of individual genes when cal-
culating connectedness, or weight their importance when training the LASSO
models. Evaluation of this change is more complicated. Potentially, calcula-
tion of the AUC score could be modified to accommodate a weighted input
set. For example, the contribution of each hidden gene along the y-axis (true
positive rate) could be changed from a 1-to-1 contribution to proportional
dependent on the sum of weights of genes in the hidden fold. It is also quite
possible that a more appropriate metric already exists. In either case, the
concept must be evaluated before inclusion in the final product.
7.4 Improving the Classifier Model
Currently, GeneSet MAPR uses an ensemble of LASSO regression models as
the classifier. (Technically, the term classifier is a little misleading, as MAPR
is more interested in the score output by the classifier than the hard class
assignment.) Other regression-based models were evaluated, such as logistic
regression, support vector machines (SVM), and elastic net. However, none
performed as well, and the drawback of more complicated models is that the
importance of individual features — and with that, the intuition of a set is
intrer-related — is often lost.
One option that would be good to explore is the use of independent compo-
nent analysis (ICA) as an approach to feature reduction. Like LASSO, ICA
identifies correlated features and can reduce the feature space to a small num-
ber of orthogonal features, which are weighted combinations of the original
features, or mixing weights [57]. Unlike LASSO, the results can be deter-
ministic. That is, from one run to another for two highly correlated features,
LASSO may not zero-weight the same feature each time. The downside of
ICA is that extracting individual feature importance from a combination
of reduced-dimensionality mixing weights is a little more complicated, espe-
cially since ICA is likely to assign negative weights to many features. An
alternative to ICA is non-negative matrix factorization (NMF), which pro-
duces purely additive mixing weights but requires the original feature values
be non-negative [58]. Once these issues are addressed, either ICA or NMF
could be swapped in, in place of the LASSO model.
Additionally, the framework was created to allow bootstrapping, where mul-
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tiple classifiers are run in sequence. At each round of training, the classifier
model sets aside those items which it can easily classify and passes the more
difficult items on to the next classifier. One issue to be addressed here is how
to avoid overfitting. Another is how to return feature importance, as some
items will pass through multiple classifiers as others will not. Although the
framework is in place, this approach has yet to be properly evaluated.
Finally, the idea was raised that if the genes within the training set could
be clustered, then separate classifiers could be trained on those clusters.
However, how to cluster a set of items in an unsupervised manner when it is
unknown whether an appropriate clustering even exists is a body of research
unto itself. We deemed that the random sub-sampling of training data in
Chapter 4 adequately addresses this problem. Time permitting, this would
be an interesting avenue to explore.
7.5 Clustering Meta-Paths
As mentioned in Chapter 5, there may be little intuitive difference between
meta-paths mi = (Ho, Bp, Ho), mj = (Ho, Tm, Ho), or mk = (Bp, Ho, Ho).
The user may appreciate simply being shown that the group of meta-paths
M = mi,mj,mk was uniquely important, as opposed to seeing the weights
of the individual paths relative to each other. As such, an alternative to
changing the classifier, such as implementing ICA or NMF, would be to
group highly correlated meta-paths. Then, representative meta-paths from
each group could be passed to the LASSO model, or else aggregated feature
importance weights could be grouped under the corresponding representative
meta-path. For example, once the meta-path features have been calculated
for a gene set, hierarchical clustering could be used to define a few high-level
“classes” of meta-paths. Then the feature importance score would highlight
which classes of meta-path are most prominent within the set. Such an
approach may be moot if the following section is implemented.
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7.6 Selective Computation of Meta-Paths
It may be possible to identify meta-paths that are likely to be correlated
before computing them. Note that this is slightly different than the previous
section, which proposes grouping meta-paths by their correlation of impor-
tance to a gene set. Instead, this section proposes examining the components
of a potential meta-path — the adjacency matrices — to compare how highly
correlated they are across the entire network. If two edge types are highly
correlated across the network, then the meta-path crafted from those two
edge types is unlikely new information. Similarly, if a length-2 meta-path is
roughly the same as an already-existing edge type, then we may wish to skip
computing the resulting length-3 meta-path.
Indeed, we see in the feature importance lists of Chapter 5 that simi-
lar length-3 meta-paths with minor variations tend to be assigned similar
weights. If we can decide upfront how to be selective in computing meta-
paths, essentially pruning them, then we can further reduce the time required
for the network pre-processing and feature generation steps.
7.7 Including Other Species
As originally envisioned, GeneSet MAPR would consider connections to genes
outside the target species. Often, experiments can be performed on another
species, such as mice, that cannot be performed on humans. What we might
expect to see in this case is a human gene relate to a mouse gene through ho-
mology or orthology, that mouse gene relate to another through experimental
evidence, and finally that second mouse gene relate back to a human gene.
The result would follow a meta-path along the lines of m = Ho,Ex,Ho,
where Ho is homology and Ex the edge type relating the experimental evi-
dence.
A few options exist, each with trade-offs. The most straightforward would
be to expand the gene-gene matrices to include mouse genes, increasing the
burden on memory and computation. Another option would be to treat the
non-human genes the same way as annotation terms, where the nodes are
removed and edges are redrawn between pairs of human genes. Unfortu-
nately, this removes the ability to connect directly from one non-human gene
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to another. Finally, a compromise could be crafted where there exist intra-
species matrices and inter-species matrices. When calculating meta-paths,
then, the algorithm would need to be aware of when a meta-path crosses
from one species to another. Such a consideration is feasible, but requires
some changes to the network pre-processing code to allow for it.
7.7.1 Beyond Star Networks
A star network is one wherein there exists a central node type. Other node
types connect to the central node, but never to each other. The network used
in this paper is a star network, where gene nodes are the central node type,
and various annotation nodes connect to those. However, as mentioned in
Chapter 3, the GO subnetwork has its own hierarchy where annotation terms
are interrelated. Including this would break the star network assumption.
The same compromise suggested to incorporate additional species above
could also address the issue of inter-connections between annotation terms.
In this case, three types of matrices would exist: gene-gene, a transitional
gene-term, and term-term. Care would be taken when crafting the meta-
paths to ensure the path began and ended on a gene node, and to select the
appropriate transition and term-term matrices. This may require slightly
more attention from the provider of the network to ensure the file is formatted
properly, but the flexibility to allow term-term and inter-species connections
may be worth it.
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CHAPTER 8
CONCLUSION
In this thesis, we present GeneSet MAPR, an algorithm for finding items in
a network that are similar to an input set while offering an intuitive descrip-
tion of what makes the set unique. We simultaneously show the utility of
connectedness over meta-paths to identify unique patterns while addressing
some common concerns about big data and machine learning approaches.
The method used by MAPR, outlined in Chapter 4, shows an improvement
over other methods at the task of set membership prediction, as seen in Chap-
ter 5. Moreover, it accomplishes this while being readily adaptable to other
and more complex tasks, several of which are detailed in Chapter 7. It is our
belief that this flexibility is due largely to the treatment of the underlying
subnetworks and their structure.
We provide a detailed example of an application to the genomics domain
in Chapter 6. There we show how MAPR can leverage a wide array of
established domain knowledge to emphasize connections and trends within a
researcher’s input set, helping to guide her towards more efficient discovery.
This is especially useful in the case where a gene set is created from a small
sample of patients, and a desire to use p-value as a threshold can lead to
errors of magnitude: both a high likelihood of omitting relevant items and
an exaggerated effect size for those that do meet the threshold. We show
that MAPR is able to add context to the (sometimes under-appreciated)
uncertainty of statistical analysis and draw attention to items where further
research appears promising.
We show that meta-paths can be a valuable way of exploring patterns
within a network. Further, we show it is possible to automatically identify
which meta-paths are most unique within a set, removing from the user the
burdens of preselecting important meta-paths, defining expected number or
size of clusters, or otherwise seeding the analysis in some fashion. Of course,
in the true spirit of ensemble learning we believe the method behind MAPR is
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best used in conjunction with additional approaches to quantifying network
patterns, such as random walks or clustering.
Given the uncertain and incomplete nature of our knowledge in the ge-
nomics domain, it is in some ways remarkable that GeneSet MAPR — or
any method — performs as well as it does. We believe the use of network
structure to capture multi-step connections shows the most potential for ex-
posing hidden dependencies between items in this and many other domains.
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APPENDIX A
SUMMARY OF ALL TESTED GENE SETS
Table A.1 contains an entry for every gene set tested in Chapter 5. For each
set, the collection of which it was a part and the number of genes in the set
are indicated. The next three columns relate to the node degree for genes in
the set. The median degree for the set is followed by the proportional change
to the median degree for the top-N genes ranked by GeneSet MAPR. For
example, if the original set contained 50 genes with a median degree of 100,
and the top 50 genes returned by MAPR had a median degree of 210, then
a value of 2.1 indicates the proportional change in the median from 100 to
210. The column ∆200+ indicates the difference in proportion of genes with
a degree of 200 or greater. For example, if a set of 100 genes contained 20
with degree at or above 200 (a proportion of 0.2), and the top 100 MAPR
genes contained 30 (a proportion of 0.3), then a value of positive 0.1 indicates
this difference. The final three columns show the AUC achieved by MAPR,
DRaWR, and LASSO ensemble, respectively.
Table A.1: All Tested Gene Sets with Node Degree Statistics and Method
AUC Values
Collection Gene Set Size Median
Degree
∆Med ∆200+ MAPR
AUC
DRaWR
AUC
LASSO
AUC
Achilles 22RV1 PROSTATE 141 119 5.4 0.65 0.679 0.559 0.561
Achilles 697 HAEMATOPOIETIC
AND LYMPHOID TISSUE
294 107 1.4 0.33 0.685 0.637 0.538
Achilles 786O KIDNEY 167 153 4.5 0.52 0.726 0.609 0.689
Achilles A1207 CENTRAL NERVOUS
SYSTEM
295 132 1.5 0.37 0.711 0.608 0.581
Achilles A172 CENTRAL NERVOUS
SYSTEM
171 122 4.7 0.52 0.704 0.571 0.648
Achilles A204 SOFT TISSUE 182 156 2.1 0.46 0.775 0.633 0.739
Achilles A2058 SKIN 222 142 2.4 0.45 0.759 0.667 0.692
Achilles A549 LUNG 152 131 4.6 0.51 0.694 0.542 0.647
Achilles A673 BONE 194 112 1.4 0.42 0.695 0.594 0.594
Achilles ACHN KIDNEY 234 134 2.0 0.45 0.743 0.612 0.643
Achilles AGS STOMACH 439 130 1.8 0.41 0.731 0.693 0.703
Achilles AM38 CENTRAL NERVOUS
SYSTEM
191 143 4.0 0.61 0.706 0.594 0.656
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Collection Gene Set Size Median
Degree
∆Med ∆200+ MAPR
AUC
DRaWR
AUC
LASSO
AUC
Achilles AML193 HAEMATOPOI-
ETIC AND LYMPHOID
TISSUE
222 129 4.2 0.65 0.702 0.559 0.663
Achilles ASPC1 PANCREAS 191 121 1.2 0.31 0.720 0.633 0.648
Achilles BT20 BREAST 175 137 2.5 0.39 0.728 0.658 0.695
Achilles BT474 BREAST 304 137 2.5 0.53 0.731 0.629 0.670
Achilles BXPC3 PANCREAS 135 131 5.4 0.64 0.748 0.606 0.712
Achilles C2BBE1 LARGE INTESTINE 189 115 2.9 0.37 0.681 0.543 0.614
Achilles C32 SKIN 254 127 0.8 0.24 0.703 0.620 0.627
Achilles CADOES1 BONE 228 116 1.2 0.29 0.689 0.606 0.521
Achilles CAL120 BREAST 171 151 3.6 0.57 0.757 0.658 0.727
Achilles CAL51 BREAST 199 100 1.4 0.33 0.681 0.594 0.552
Achilles CALU1 LUNG 295 123 2.8 0.58 0.677 0.654 0.532
Achilles CAOV3 OVARY 148 143 2.8 0.36 0.750 0.606 0.694
Achilles CAOV4 OVARY 242 133 0.9 0.23 0.754 0.680 0.683
Achilles CAS1 CENTRAL NERVOUS
SYSTEM
396 122 3.0 0.60 0.701 0.583 0.594
Achilles CFPAC1 PANCREAS 263 120 2.7 0.54 0.723 0.548 0.572
Achilles CH157MN CENTRAL NER-
VOUS SYSTEM
194 128 3.8 0.59 0.711 0.652 0.694
Achilles COLO205 LARGE INTES-
TINE
238 132 3.1 0.50 0.708 0.579 0.617
Achilles COLO704 OVARY 247 123 1.5 0.44 0.724 0.698 0.675
Achilles COLO741 SKIN 111 125 6.8 0.59 0.676 0.625 0.634
Achilles COLO783 SKIN 292 137 1.8 0.38 0.709 0.605 0.584
Achilles CORL23 LUNG 365 97 0.6 0.18 0.671 0.631 0.513
Achilles COV362 OVARY 435 132 1.8 0.44 0.734 0.668 0.700
Achilles COV434 OVARY 137 134 3.2 0.51 0.693 0.536 0.645
Achilles COV504 OVARY 195 121 2.9 0.43 0.685 0.580 0.627
Achilles COV644 OVARY 169 131 1.2 0.38 0.730 0.637 0.689
Achilles DBTRG05MG CENTRAL
NERVOUS SYSTEM
158 122 0.6 0.17 0.699 0.599 0.624
Achilles DKMG CENTRAL NERVOUS
SYSTEM
144 133 2.2 0.36 0.683 0.594 0.608
Achilles DLD1 LARGE INTESTINE 339 116 1.1 0.32 0.699 0.666 0.582
Achilles EFE184 ENDOMETRIUM 296 124 1.1 0.35 0.726 0.692 0.682
Achilles EFM19 BREAST 427 133 1.6 0.38 0.748 0.671 0.702
Achilles EFO21 OVARY 490 134 1.8 0.45 0.738 0.662 0.691
Achilles EFO27 OVARY 76 116 1.1 0.29 0.700 0.574 0.732
Achilles EW8 BONE 173 125 2.8 0.53 0.690 0.527 0.641
Achilles EWS502 BONE 308 104 0.5 0.19 0.681 0.609 0.574
Achilles F36P HAEMATOPOIETIC
AND LYMPHOID TISSUE
268 121 2.8 0.51 0.691 0.636 0.675
Achilles GB1 CENTRAL NERVOUS
SYSTEM
138 131 2.7 0.50 0.702 0.647 0.624
Achilles GP2D LARGE INTESTINE 333 129 3.0 0.59 0.715 0.611 0.644
Achilles HCC1187 BREAST 342 125 3.3 0.64 0.704 0.574 0.613
Achilles HCC1395 BREAST 126 128 4.4 0.36 0.719 0.605 0.671
Achilles HCC1954 BREAST 343 134 2.5 0.54 0.728 0.631 0.672
Achilles HCC2218 BREAST 324 146 2.3 0.47 0.731 0.685 0.673
Achilles HCC2814 LUNG 229 136 2.6 0.46 0.707 0.639 0.656
Achilles HCC364 LUNG 236 125 3.4 0.48 0.727 0.581 0.628
Achilles HCC44 LUNG 189 126 3.8 0.60 0.729 0.551 0.648
Achilles HCC70 BREAST 327 165 1.5 0.33 0.786 0.710 0.766
Achilles HCC827 LUNG 201 127 3.8 0.54 0.705 0.613 0.603
Achilles HCC827GR5 LUNG 119 138 2.7 0.57 0.735 0.619 0.670
Achilles HCT116 LARGE INTESTINE 369 147 2.3 0.54 0.772 0.679 0.732
Achilles HEC1A ENDOMETRIUM 170 118 0.6 0.21 0.693 0.549 0.598
Achilles HEYA8 OVARY 133 111 1.3 0.35 0.705 0.653 0.656
Achilles HL60 HAEMATOPOIETIC
AND LYMPHOID TISSUE
541 114 2.1 0.41 0.672 0.591 0.600
Achilles HLF LIVER 99 134 0.6 0.31 0.719 0.629 0.710
Achilles HNT34 HAEMATOPOIETIC
AND LYMPHOID TISSUE
263 120 3.8 0.56 0.674 0.566 0.580
Achilles HPAC PANCREAS 142 125 4.2 0.39 0.763 0.686 0.718
Achilles HPAFII PANCREAS 244 125 3.0 0.59 0.709 0.594 0.654
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Achilles HS683 CENTRAL NERVOUS
SYSTEM
244 127 3.5 0.63 0.728 0.660 0.652
Achilles HS766T PANCREAS 112 109 5.7 0.46 0.706 0.572 0.669
Achilles HS944T SKIN 226 126 2.6 0.56 0.657 0.594 0.569
Achilles HT1197 URINARY TRACT 189 138 2.4 0.34 0.728 0.638 0.654
Achilles HT29 LARGE INTESTINE 366 143 1.8 0.42 0.777 0.714 0.747
Achilles HT55 LARGE INTESTINE 470 133 2.9 0.60 0.706 0.634 0.655
Achilles HUG1N STOMACH 282 128 3.2 0.63 0.700 0.604 0.607
Achilles HUTU80 SMALL INTESTINE 182 120 1.2 0.33 0.712 0.643 0.653
Allen Brain DN AMYGDALOHIP-
POCAMPAL AREA
295 77 0.0 −0.01 0.673 0.603 0.518
Allen Brain DN INTERMEDIATE PART
OF R3B
295 96 0.3 −0.07 0.664 0.594 0.507
Allen Brain DN INTERNAL GRANULAR
LAYER OF CBVCX
298 102 2.4 0.48 0.738 0.656 0.644
Allen Brain DN LATEROSTRIATAL
STRIPE
295 71 0.2 0.08 0.551 0.586 0.489
Allen Brain DN LAYER 2 OF OCX 295 97 0.4 0.15 0.715 0.640 0.721
Allen Brain DN M2 PART OF
PARARUBRAL NUCLEUS
295 76 0.0 0.02 0.603 0.546 0.520
Allen Brain DN MANTLE ZONE OF
PHYB P
293 81 0.5 0.12 0.629 0.535 0.505
Allen Brain DN MANTLE ZONE OF
R5BL
294 94 0.1 0.00 0.676 0.607 0.468
Allen Brain DN MANTLE ZONE OF
TPAA
296 93 3.9 0.53 0.688 0.608 0.611
Allen Brain DN R5 PART OF PAR-
VOCELLULAR MEDIAL
VESTIBULAR NUCLEUS
295 71 1.2 0.21 0.623 0.552 0.492
Allen Brain DN R7 PART OF SPINAL
VESTIBULAR NUCLEUS
296 89 4.0 0.55 0.689 0.601 0.519
Allen Brain DN SEPTODIAGONAL
TRANSITION AREA
297 89 0.6 0.21 0.652 0.571 0.549
Allen Brain DN SUBICULUM VENTRAL
PART MOLECULAR LAYER
294 74 0.0 −0.06 0.660 0.578 0.536
Allen Brain DN ZONA INCERTA COM-
PLEX
293 75 1.4 0.30 0.570 0.520 0.469
Allen Brain UP AGRANULAR INSU-
LAR AREA DORSAL PART
LAYER 6A
298 87 0.1 0.05 0.667 0.548 0.563
Allen Brain UP ANTERIOR PART OF
INT
290 66 0.2 −0.02 0.575 0.559 0.499
Allen Brain UP BED NUCLEI OF THE
STRIA TERMINALIS ANTE-
RIOR DIVISION J
295 96 0.0 −0.02 0.712 0.678 0.537
Allen Brain UP COLLICULAR ROSTRAL
MIDBRAIN TECTUM
297 98 2.1 0.33 0.615 0.546 0.565
Allen Brain UP DORSAL ENTOPEDUN-
CULAR NUCLEUS
296 92 −0.3 −0.03 0.646 0.527 0.537
Allen Brain UP DORSAL PEDUNCULAR
AREA LAYER 5
296 89 3.4 0.57 0.639 0.553 0.551
Allen Brain UP FIELD CA1 STRATUM
ORIENS
336 96 1.5 0.31 0.696 0.579 0.532
Allen Brain UP INTERMEDIATE STRA-
TUM OF R9TR
294 81 2.7 0.43 0.608 0.598 0.497
Allen Brain UP ISTHMIC LIMINAL PART
OF THE PERIAQUEDUCTAL
GRAY
297 78 0.2 0.20 0.597 0.567 0.490
Allen Brain UP ISTHMIC PART OF
BASOLATERAL ISTHMIC
RETICULAR FORMATION
298 80 0.1 0.00 0.658 0.585 0.469
Allen Brain UP LATERAL DORSAL NU-
CLEUS OF THALAMUS
291 83 1.3 0.29 0.667 0.618 0.539
Allen Brain UP LIMINAL ALAR DOMAIN
OF M2
294 79 0.1 0.03 0.619 0.584 0.510
Allen Brain UP MANTLE ZONE OF
R6VE
296 70 −0.2 −0.10 0.634 0.566 0.510
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Allen Brain UP MEDIAL AMYGDALA
POSTERODORSAL PART
298 99 2.4 0.39 0.640 0.601 0.493
Allen Brain UP ORBITAL AREA VEN-
TROLATERAL PART LAYER
2 3
296 92 1.7 0.30 0.630 0.599 0.522
Allen Brain UP PERIVENTRICULAR
STRATUM OF M1B
299 87 0.0 −0.02 0.660 0.626 0.528
Allen Brain UP PERIVENTRICULAR
STRATUM OF R9LIM
295 85 0.0 −0.02 0.646 0.556 0.500
Allen Brain UP PONTINE RETICULAR
NUCLEUS CAUDAL PART
300 73 −0.2 −0.04 0.609 0.560 0.491
Allen Brain UP PRIMARY SO-
MATOSENSORY AREA
TRUNK LAYER 4
293 86 0.9 0.20 0.615 0.563 0.519
Allen Brain UP R2 PART OF BASOIN-
TERMEDIATE RETICULAR
FORMATION
299 70 0.8 0.15 0.650 0.556 0.529
Allen Brain UP R2 PART OF THE
VENTRAL PARVICELLULAR
RETICULAR FORMATION
297 76 0.2 0.02 0.614 0.576 0.510
Allen Brain UP R5 PART OF
POSTEROVENTRAL
COCHLEAR NUCLEUS
290 93 1.4 0.33 0.640 0.520 0.567
Allen Brain UP R9 PART OF THE
VESTIBULAR COLUMN
301 88 0.7 0.10 0.591 0.604 0.469
Allen Brain UP SUBPALLIAL SEPTUM 295 84 −0.1 −0.02 0.692 0.604 0.501
Allen Brain UP SUPERFICIAL STRA-
TUM OF CEREBELLAR
HEMISPHERE
294 95 0.1 0.02 0.680 0.598 0.551
Allen Brain UP SUPERFICIAL STRA-
TUM OF TG
298 84 −0.2 −0.10 0.643 0.624 0.552
dbGaP Alcoholism-93 93 90 0.1 0.03 0.692 0.616 0.649
dbGaP Alzheimer Disease-79 79 101 0.2 0.24 0.678 0.572 0.612
dbGaP Amyotrophic Lateral
Sclerosis-76
76 87 0.1 0.04 0.675 0.595 0.654
dbGaP Arteries-88 88 94 0.5 0.30 0.667 0.643 0.604
dbGaP Asthma-106 106 122 2.7 0.48 0.716 0.565 0.696
dbGaP Attention Deficit Disorder
with Hyperactivity-99
99 90 −0.1 0.26 0.676 0.567 0.615
dbGaP Bipolar Disorder-102 102 75 0.1 0.05 0.656 0.710 0.614
dbGaP Blood Pressure-447 447 90 0.4 0.10 0.689 0.642 0.532
dbGaP Body Height-379 379 100 0.7 0.23 0.687 0.648 0.619
dbGaP Body Mass Index-434 434 85 0.4 0.05 0.699 0.694 0.575
dbGaP Body Weight-212 212 88 2.0 0.36 0.681 0.628 0.563
dbGaP Body Weights and Measures-
85
85 95 2.4 0.37 0.653 0.488 0.587
dbGaP Bone Density-73 73 113 0.3 0.15 0.667 0.586 0.637
dbGaP C Reactive Protein-87 87 93 −0.1 −0.02 0.681 0.619 0.595
dbGaP Cholesterol HDL-354 354 88 0.1 −0.02 0.659 0.648 0.488
dbGaP Cholesterol LDL-301 301 97 0.1 0.03 0.696 0.604 0.519
dbGaP Cholesterol-267 267 95 0.4 0.17 0.699 0.621 0.507
dbGaP Coronary Artery Disease-201 201 91 3.5 0.52 0.688 0.611 0.521
dbGaP Coronary Disease-81 81 94 0.3 0.10 0.675 0.595 0.649
dbGaP Creatinine-91 91 102 0.1 0.11 0.712 0.669 0.618
dbGaP Diabetes Mellitus Type 1-74 74 99 3.4 0.50 0.576 0.693 0.601
dbGaP Diabetes Mellitus Type 2-84 84 99 3.1 0.33 0.721 0.662 0.701
dbGaP Diabetes Mellitus-69 69 87 −0.2 0.03 0.720 0.658 0.694
dbGaP Echocardiography-271 271 87 0.1 0.02 0.675 0.670 0.523
dbGaP Elbow-71 71 95 0.3 0.09 0.673 0.451 0.612
dbGaP Electrocardiography-84 84 114 0.1 0.04 0.716 0.685 0.667
dbGaP Erythrocyte Count-114 114 91 0.2 0.16 0.699 0.609 0.598
dbGaP Fibrinogen-84 84 122 1.3 0.36 0.707 0.635 0.655
dbGaP Glucose-144 144 72 0.0 −0.03 0.691 0.614 0.594
dbGaP Heart Failure-182 182 82 0.3 0.13 0.637 0.604 0.563
dbGaP Heart Rate-155 155 91 0.1 0.17 0.681 0.657 0.526
dbGaP Hemoglobin A Glycosylated-
125
125 96 3.3 0.35 0.630 0.602 0.588
Continued on next page→
74
Table A.1 – continued from previous page
Collection Gene Set Size Median
Degree
∆Med ∆200+ MAPR
AUC
DRaWR
AUC
LASSO
AUC
dbGaP Hip-198 198 92 0.4 0.12 0.672 0.671 0.515
dbGaP Insulin-87 87 124 2.0 0.38 0.713 0.623 0.633
dbGaP Iron-152 152 87 −0.2 −0.08 0.720 0.660 0.565
dbGaP Lipids-85 85 83 0.2 0.01 0.672 0.664 0.608
dbGaP Lipoproteins VLDL-84 84 104 2.8 0.56 0.686 0.693 0.572
dbGaP Lipoproteins-79 79 82 −0.1 0.05 0.740 0.699 0.657
dbGaP Lupus Erythematosus
Systemic-86
86 107 4.4 0.44 0.622 0.546 0.633
dbGaP Macular Degeneration-118 118 76 1.5 0.29 0.591 0.525 0.578
dbGaP Multiple Sclerosis-82 82 111 3.8 0.51 0.617 0.660 0.609
dbGaP Myocardial Infarction-228 228 86 0.2 −0.06 0.696 0.652 0.524
dbGaP Neuroblastoma-100 100 84 −0.2 −0.06 0.624 0.511 0.591
dbGaP Parkinson Disease-130 130 76 5.8 0.41 0.664 0.628 0.579
dbGaP Respiratory Function Tests-
148
148 89 0.1 0.03 0.719 0.695 0.589
dbGaP Schizophrenia-82 82 90 0.6 0.24 0.666 0.575 0.577
dbGaP Stroke-284 284 83 0.1 −0.01 0.667 0.613 0.510
dbGaP Triglycerides-240 240 85 0.1 −0.03 0.673 0.643 0.497
dbGaP Tunica Media-103 103 100 −0.3 −0.01 0.704 0.681 0.631
dbGaP Waist Circumference-144 144 94 −0.1 −0.04 0.673 0.623 0.581
dbGaP Waist Hip Ratio-92 92 76 2.2 0.36 0.647 0.694 0.612
Enrichr Path NCI DIRECT P53 EFFEC-
TORS HOMO SAPIENS
67C3B75D 6191 11E5 8AC5
0
135 218 0.0 −0.01 0.936 0.840 0.870
Enrichr Path WIKIPATH ADIPOGENESIS
GENES MUS MUSCULUS
WP447
128 300 −0.6 −0.27 0.944 0.965 0.912
Enrichr Path WIKIPATH ADIPOGENESIS
HOMO SAPIENS WP236
129 302 −0.5 −0.26 0.951 0.970 0.926
Enrichr Path WIKIPATH ALZHEIMERS
DISEASE HOMO SAPIENS
WP2059
120 193 −0.4 −0.28 0.899 0.988 0.893
Enrichr Path WIKIPATH BDNF SIGNAL-
ING PATHWAY HOMO SAPI-
ENS WP2380
143 453 0.0 0.02 0.969 0.974 0.937
Enrichr Path WIKIPATH CALCIUM REGU-
LATION IN THE CARDIAC
CELL HOMO SAPIENS WP
149 156 −0.1 −0.10 0.989 0.978 0.970
Enrichr Path WIKIPATH CALCIUM REGU-
LATION IN THE CARDIAC
CELL MUS MUSCULUS WP
150 153 −0.1 −0.05 0.990 0.980 0.984
Enrichr Path WIKIPATH CELL CYCLE
HOMO SAPIENS WP179
103 324 −0.1 −0.12 0.972 0.970 0.955
Enrichr Path WIKIPATH CHEMOKINE
SIGNALING PATHWAY MUS
MUSCULUS WP2292
164 244 −0.1 −0.06 0.991 0.995 0.982
Enrichr Path WIKIPATH CIRCADIAN
RYTHM RELATED GENES
HOMO SAPIENS WP3594
200 228 1.3 0.18 0.928 0.935 0.977
Enrichr Path WIKIPATH EGFR1 SIGNAL-
ING PATHWAY MUS MUS-
CULUS WP572
171 366 0.1 −0.05 0.969 0.907 0.939
Enrichr Path WIKIPATH ELECTRON
TRANSPORT CHAIN HOMO
SAPIENS WP111
103 127 0.0 −0.02 0.991 0.999 0.990
Enrichr Path WIKIPATH ESC PLURIPO-
TENCY PATHWAYS MUS
MUSCULUS WP339
116 335 −0.4 −0.17 0.992 0.993 0.978
Enrichr Path WIKIPATH FOCAL AD-
HESION HOMO SAPIENS
WP306
187 313 0.1 −0.01 0.991 0.992 0.988
Enrichr Path WIKIPATH FOCAL ADHE-
SION MUS MUSCULUS
WP85
182 293 0.2 0.00 0.986 0.982 0.980
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Enrichr Path WIKIPATH GPCRS CLASS A
RHODOPSIN LIKE HOMO
SAPIENS WP455
258 202 −0.1 −0.08 0.989 0.992 0.953
Enrichr Path WIKIPATH GPCRS CLASS
A RHODOPSIN LIKE MUS
MUSCULUS WP189
171 200 −0.1 −0.13 0.989 0.994 0.964
Enrichr Path WIKIPATH INSULIN SIG-
NALING HOMO SAPIENS
WP481
160 384 0.2 0.04 0.976 0.980 0.957
Enrichr Path WIKIPATH INTEGRATED
BREAST CANCER PATH-
WAY HOMO SAPIENS
WP1984
152 368 0.4 0.11 0.917 0.906 0.876
Enrichr Path WIKIPATH MAPK SIGNAL-
ING PATHWAY MUS MUS-
CULUS WP493
155 378 0.0 0.00 0.982 0.972 0.981
Enrichr Path WIKIPATH METAPATHWAY
BIOTRANSFORMATION
HOMO SAPIENS WP702
176 76 0.1 −0.02 0.994 0.997 0.992
Enrichr Path WIKIPATH MRNA PRO-
CESSING HOMO SAPIENS
WP411
126 187 0.0 −0.06 0.989 0.975 0.967
Enrichr Path WIKIPATH MYOMETRIAL
RELAXATION AND CON-
TRACTION PATHWAYS
HOMO SA
155 194 0.4 0.12 0.976 0.957 0.955
Enrichr Path WIKIPATH MYOMETRIAL
RELAXATION AND CON-
TRACTION PATHWAYS
MUS MUS
151 191 1.3 0.16 0.974 0.974 0.965
Enrichr Path WIKIPATH NEURAL CREST
DIFFERENTIATION HOMO
SAPIENS WP2064
101 311 −0.5 −0.29 0.972 0.977 0.947
Enrichr Path WIKIPATH NRF2 PATHWAY
HOMO SAPIENS WP2884
145 90 1.9 0.32 0.970 0.937 0.966
Enrichr Path WIKIPATH ODORANT
GPCRS MUS MUSCULUS
WP1397
109 96 0.6 0.05 0.977 0.983 0.970
Enrichr Path WIKIPATH PLURINET-
WORK MUS MUSCULUS
WP1763
283 303 0.2 0.01 0.940 0.929 0.888
Enrichr Path WIKIPATH PODNET PRO-
TEIN PROTEIN INTERAC-
TIONS IN THE PODOCYTE
M
303 195 0.5 0.11 0.922 0.882 0.885
Enrichr Path WIKIPATH PURINE
METABOLISM MUS MUS-
CULUS WP2185
158 107 0.1 0.05 0.997 0.998 0.993
Enrichr Path WIKIPATH REGULATION
OF ACTIN CYTOSKELE-
TON HOMO SAPIENS
WP51
148 248 0.0 −0.01 0.987 0.993 0.986
Enrichr Path WIKIPATH SENESCENCE
AND AUTOPHAGY IN
CANCER HOMO SAPIENS
WP615
105 287 0.6 −0.02 0.947 0.978 0.918
Enrichr Path WIKIPATH SIDS SUSCEPTI-
BILITY PATHWAYS HOMO
SAPIENS WP706
159 249 −0.1 −0.06 0.939 0.918 0.917
Enrichr Path WIKIPATH SPINAL CORD
INJURY HOMO SAPIENS
WP2431
118 266 −0.5 −0.25 0.925 0.916 0.891
Enrichr Path WIKIPATH TGF BETA SIG-
NALING PATHWAY HOMO
SAPIENS WP366
132 438 0.1 −0.10 0.973 0.967 0.947
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Enrichr Path WIKIPATH TNF ALPHA NF
KB SIGNALING PATHWAY
MUS MUSCULUS WP246
178 315 0.0 −0.07 0.962 0.946 0.922
Enrichr Path WIKIPATH TOLL LIKE RE-
CEPTOR SIGNALING PATH-
WAY HOMO SAPIENS WP75
102 353 −0.3 −0.09 0.996 0.999 0.997
Enrichr Path WIKIPATH WNT SIG-
NALING PATHWAY AND
PLURIPOTENCY HOMO
SAPIENS WP
101 302 0.4 0.04 0.977 0.961 0.966
Enrichr Path WIKIPATH WNT SIGNAL-
ING PATHWAY NETPATH
MUS MUSCULUS WP539
106 428 0.1 −0.01 0.977 0.981 0.971
Enrichr Path WIKIPATH XPODNET PRO-
TEIN PROTEIN INTERAC-
TIONS IN THE PODOCYTE
802 193 0.3 0.11 0.909 0.889 0.852
Enrichr Pheno DBGAP BODY MASS INDEX 435 84 0.4 0.00 0.695 0.671 0.570
Enrichr Pheno DBGAP CHOLESTEROL 265 96 1.1 0.29 0.648 0.541 0.506
Enrichr Pheno DBGAP CHOLESTEROL
HDL
351 88 0.0 −0.03 0.685 0.670 0.497
Enrichr Pheno DBGAP CHOLESTEROL
LDL
299 98 0.1 0.04 0.684 0.626 0.523
Enrichr Pheno DBGAP CORONARY
ARTERY DISEASE
201 91 3.5 0.49 0.675 0.610 0.502
Enrichr Pheno DBGAP ECHOCARDIOGRA-
PHY
268 88 0.1 0.00 0.679 0.665 0.512
Enrichr Pheno DBGAP HEMOGLOBIN A
GLYCOSYLATED
126 96 4.7 0.52 0.620 0.609 0.595
Enrichr Pheno DBGAP HIP 198 92 0.7 0.18 0.656 0.677 0.595
Enrichr Pheno DBGAP MACULAR DEGEN-
ERATION
116 76 1.4 0.30 0.611 0.667 0.558
Enrichr Pheno DBGAP NEUROBLASTOMA 101 84 −0.3 −0.07 0.632 0.511 0.612
Enrichr Pheno DBGAP TUNICA MEDIA 104 100 0.2 0.19 0.687 0.637 0.598
Enrichr Pheno DBGAP WAIST CIRCUM-
FERENCE
143 94 −0.1 0.03 0.658 0.642 0.602
Enrichr Pheno HPO ABDOMINAL PAIN HP
0002027
118 162 −0.3 −0.04 0.876 0.840 0.804
Enrichr Pheno HPO AUTOSOMAL RECES-
SIVE INHERITANCE HP
0000007
1,706 108 0.0 0.00 0.848 0.819 0.775
Enrichr Pheno HPO BLEPHAROPHIMOSIS
HP 0000581
103 161 2.9 0.23 0.827 0.802 0.771
Enrichr Pheno HPO CAMPTODACTYLY
OF FINGER HP 0100490
121 126 1.2 0.21 0.872 0.836 0.765
Enrichr Pheno HPO CEREBRAL CORTICAL
ATROPHY HP 0002120
152 125 0.1 0.13 0.787 0.762 0.724
Enrichr Pheno HPO ELEVATED HEPATIC
TRANSAMINASES HP
0002910
111 105 −0.2 −0.05 0.866 0.837 0.823
Enrichr Pheno HPO EPICANTHUS HP
0000286
232 136 1.2 0.23 0.849 0.791 0.726
Enrichr Pheno HPO FRONTAL BOSSING
HP 0002007
210 141 0.1 0.08 0.850 0.808 0.811
Enrichr Pheno HPO HEPATOMEGALY HP
0002240
329 115 0.0 0.03 0.864 0.844 0.783
Enrichr Pheno HPO HETEROGENEOUS HP
0001425
148 136 −0.1 −0.05 0.880 0.874 0.779
Enrichr Pheno HPO HYPOPLASIA OF THE
CORPUS CALLOSUM HP
0002079
102 109 −0.6 −0.15 0.791 0.770 0.735
Enrichr Pheno HPO MALAR FLATTENING
HP 0000272
185 139 1.4 0.20 0.846 0.771 0.778
Enrichr Pheno HPO MULTICYSTIC KID-
NEY DYSPLASIA HP
0000003
100 134 6.6 0.47 0.890 0.903 0.885
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Enrichr Pheno HPO OPACIFICATION OF
THE CORNEAL STROMA
HP 0007759
135 104 −0.3 0.04 0.877 0.812 0.832
Enrichr Pheno HPO OPTIC ATROPHY HP
0000648
360 109 0.4 0.16 0.862 0.823 0.771
Enrichr Pheno HPO PATENT DUCTUS AR-
TERIOSUS HP 0001643
124 161 −0.2 −0.04 0.855 0.807 0.814
Enrichr Pheno HPO PECTUS EXCAVATUM
HP 0000767
132 171 −0.5 −0.20 0.828 0.768 0.787
Enrichr Pheno HPO PES PLANUS HP
0001763
105 162 0.1 0.08 0.857 0.865 0.838
Enrichr Pheno HPO PHOTOPHOBIA HP
0000613
147 111 0.5 0.23 0.884 0.866 0.839
Enrichr Pheno HPO PROGRESSIVE DISOR-
DER HP 0003676
142 115 −0.1 0.05 0.861 0.874 0.791
Enrichr Pheno HPO PROTEINURIA HP
0000093
105 130 3.8 0.31 0.838 0.835 0.781
Enrichr Pheno HPO SKIN ULCER HP
0200042
118 173 1.4 0.26 0.849 0.801 0.785
Enrichr Pheno HPO UPSLANTED PALPE-
BRAL FISSURE HP 0000582
107 135 6.7 0.53 0.846 0.841 0.810
Enrichr Pheno HPO VOMITING HP 0002013 108 108 0.5 0.18 0.910 0.863 0.892
Enrichr Pheno OMIM EXP CARDIOMY-
OPATHY
111 280 0.7 0.08 0.949 0.947 0.919
Enrichr Pheno OMIM EXP CARDIOMY-
OPATHY DILATED
104 288 −0.1 −0.10 0.948 0.953 0.920
Enrichr Pheno OMIM EXP COLORECTAL
CANCER
102 334 0.4 0.05 0.948 0.922 0.934
Enrichr Pheno OMIM EXP DIABETES MEL-
LITUS TYPE 2
102 286 −0.1 −0.09 0.942 0.945 0.920
ESCAPE ASCL1 19796622 1,349 88 0.2 0.01 0.745 0.706 0.667
ESCAPE ATF3 19796622 DOWN 297 87 0.5 0.06 0.693 0.622 0.583
ESCAPE CHIP CNOT3 19339689 1,153 104 1.5 0.40 0.714 0.648 0.664
ESCAPE CHIP EED 16625203 633 129 0.1 0.00 0.853 0.825 0.801
ESCAPE CHIP GCN5 20946988 223 114 2.2 0.48 0.719 0.575 0.673
ESCAPE CHIP KLF4 18358816 1,303 109 1.1 0.30 0.726 0.672 0.670
ESCAPE CHIP KLF4 18555785 1,908 105 1.0 0.28 0.744 0.686 0.709
ESCAPE CHIP MYC 18555785 916 124 0.8 0.21 0.829 0.779 0.799
ESCAPE CHIP NANOG 18347094 1,464 107 0.9 0.26 0.716 0.671 0.635
ESCAPE CHIP NANOG 18358816 902 106 1.3 0.35 0.692 0.612 0.653
ESCAPE CHIP PRDM14 21183938 1,448 101 1.2 0.29 0.715 0.678 0.657
ESCAPE CHIP REST 18959480 1,752 99 0.5 0.14 0.715 0.652 0.653
ESCAPE CHIP REST 21632747 1,554 80 0.2 −0.03 0.700 0.668 0.540
ESCAPE EOMES 19796622 1,339 86 0.4 0.07 0.730 0.669 0.690
ESCAPE EOMES 19796622 DOWN 1,357 79 0.3 0.01 0.711 0.660 0.635
ESCAPE ESRRB 19136965 185 95 0.3 0.14 0.753 0.680 0.610
ESCAPE ETV3 19796622 374 80 −0.1 −0.02 0.701 0.687 0.591
ESCAPE FOXJ2 19796622 147 80 −0.3 −0.03 0.698 0.647 0.548
ESCAPE GATA3 19796622 DOWN 1,608 83 0.4 0.08 0.708 0.662 0.615
ESCAPE KLF4 18264089 DOWN 620 100 1.2 0.33 0.715 0.612 0.627
ESCAPE KLF5 20875108 DOWN 209 131 0.0 0.06 0.821 0.778 0.699
ESCAPE MESC H3K9ME3 19884255 1,925 102 0.3 0.07 0.744 0.717 0.684
ESCAPE MYCN 19796622 361 73 0.6 0.06 0.707 0.640 0.536
ESCAPE NANOG 16767105 419 89 0.6 0.15 0.706 0.638 0.652
ESCAPE NR0B1 19530134 DOWN 147 107 1.8 0.36 0.727 0.622 0.669
ESCAPE NR2F2 19796622 DOWN 823 78 0.5 0.05 0.717 0.696 0.625
ESCAPE NR5A2 19796622 621 78 0.2 −0.01 0.715 0.647 0.498
ESCAPE PANCT1 22327834 DOWN 278 89 0.6 0.15 0.768 0.734 0.618
ESCAPE POU5F1 16767105 389 92 0.6 0.17 0.732 0.658 0.627
ESCAPE PROTEIN NANOG 21589869 120 212 0.8 0.20 0.932 0.943 0.912
ESCAPE PROTEIN POU5F1 22083510 187 196 0.2 0.05 0.915 0.856 0.890
ESCAPE RAD21 21589869 505 98 1.6 0.33 0.718 0.662 0.642
ESCAPE REST 21632747 141 97 4.6 0.43 0.702 0.549 0.673
ESCAPE RHOX6 19796622 304 90 0.3 0.09 0.710 0.662 0.500
ESCAPE SOX17 20123909 DOWN 267 109 0.2 0.06 0.699 0.675 0.567
ESCAPE STAT3 19796622 DOWN 137 65 0.3 0.03 0.655 0.583 0.512
ESCAPE T 19796622 696 89 0.2 0.07 0.719 0.666 0.592
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ESCAPE TCEA3 19796622 279 79 −0.3 −0.11 0.698 0.634 0.520
ESCAPE TCEA3 19796622 DOWN 396 74 0.0 −0.07 0.696 0.648 0.589
ESCAPE ZFP281 21915945 DOWN 157 172 1.6 0.44 0.896 0.798 0.835
GeneSigDB 12747878 TABLE2 152 126 2.9 0.44 0.761 0.716 0.732
GeneSigDB 12917485 TABLE6 451 134 2.1 0.45 0.797 0.701 0.709
GeneSigDB 12917485 TABLE9 384 143 2.7 0.51 0.783 0.713 0.753
GeneSigDB 15930337 TABLES4 152 122 5.3 0.69 0.737 0.627 0.715
GeneSigDB 16081686 SUPPTABLE4 640 174 0.9 0.30 0.849 0.800 0.817
GeneSigDB 16140871 SUPPTABLE7 154 107 0.1 0.08 0.836 0.815 0.742
GeneSigDB 16166618 SUPPTABLE4 1,430 98 0.5 0.16 0.752 0.694 0.713
GeneSigDB 16440291 SUPPTABLE1 195 115 0.1 0.00 0.854 0.829 0.779
GeneSigDB 16651414 SUPP2 1,606 112 0.9 0.25 0.731 0.696 0.688
GeneSigDB 16728981 SUPPTABLE2 113 111 6.4 0.69 0.658 0.563 0.632
GeneSigDB 16735486 TABLE1 126 101 0.9 0.28 0.789 0.733 0.746
GeneSigDB 16760443 SUPPTABLE2 148 161 3.6 0.43 0.781 0.693 0.750
GeneSigDB 16790086 TABLEW1 223 193 0.6 0.13 0.904 0.840 0.867
GeneSigDB 16872506 SUPPTABLE1 1,467 122 0.7 0.19 0.818 0.765 0.799
GeneSigDB 17555561 TABLE1 966 94 2.5 0.50 0.675 0.623 0.635
GeneSigDB 17597811 SUPPTABLE6 654 101 1.4 0.38 0.721 0.672 0.681
GeneSigDB 17671232 TABLES2A 170 110 0.2 0.12 0.732 0.673 0.652
GeneSigDB 17683608 TABLES2 590 106 1.1 0.30 0.752 0.689 0.713
GeneSigDB 17894856 SUPPLIST4 203 206 2.1 0.24 0.848 0.751 0.768
GeneSigDB 18062813 GENELIST 103 128 4.6 0.38 0.779 0.603 0.756
GeneSigDB 18394172 S3GENELIST 214 103 0.2 0.10 0.800 0.742 0.731
GeneSigDB 18394172 S4GENELIST 285 92 0.2 0.05 0.699 0.604 0.622
GeneSigDB 18535662 TABLES2A 871 107 0.6 0.21 0.770 0.698 0.720
GeneSigDB 18537972 TABLES3 649 108 2.7 0.55 0.692 0.599 0.597
GeneSigDB 18593951 TABLES2 214 102 5.2 0.53 0.687 0.622 0.637
GeneSigDB 18662380 S3 ESR1 269 91 1.0 0.26 0.725 0.639 0.622
GeneSigDB 18667080 TABLES2 743 129 1.3 0.37 0.770 0.683 0.739
GeneSigDB 18927307 TABLES2 236 113 5.6 0.67 0.711 0.552 0.680
GeneSigDB 18974375 TABLES2 165 103 0.1 0.09 0.847 0.772 0.794
GeneSigDB 19043454 TABLES2 166 121 −0.1 −0.02 0.873 0.860 0.820
GeneSigDB 19061838 TABLES14 199 118 3.3 0.37 0.762 0.706 0.698
GeneSigDB 19096012 TABLES2 427 128 1.1 0.35 0.768 0.696 0.729
GeneSigDB 19185848 TABLES4 206 104 0.2 0.09 0.789 0.725 0.746
GeneSigDB 19399471 SUPPTABLE2 101 109 3.6 0.55 0.643 0.494 0.629
GeneSigDB 19904269 ST1 205 104 1.1 0.33 0.695 0.640 0.622
GeneSigDB 20035825 TABLES7A 305 86 0.1 0.04 0.723 0.639 0.602
GeneSigDB 20215513 TABLES4 177 122 3.6 0.51 0.760 0.656 0.704
GeneSigDB 20421987 TABLES4 381 82 0.1 −0.01 0.727 0.657 0.612
GeneSigDB 20436685 ST5 2 214 106 3.8 0.46 0.748 0.680 0.637
GeneSigDB 20485376 TABLES4 149 1 0.0 0.00 0.998 0.994 0.995
GEO AGING DN RAT HIPPOCAM-
PUS CA3 18 MONTHS VS 28
MONTHS GSE21681 AG
307 109 1.1 0.28 0.808 0.733 0.744
GEO DIS PERT DN DILATED
CARDIOMYOPATHY DOID
12930 HUMAN GSE42955 SA
295 92 0.4 0.18 0.717 0.639 0.556
GEO DIS PERT DN EN-
DOMETRIOSIS DOID 289
HUMAN GSE6364 SAMPLE
947
379 104 0.6 0.15 0.788 0.734 0.752
GEO DIS PERT DN MELANOMA
DOID 1909 HUMAN
GSE6887 SAMPLE 951
368 84 0.2 −0.03 0.713 0.668 0.672
GEO DIS PERT DN MENTAL RE-
TARDATION DOID 1059 HU-
MAN GSE6575 SAMPLE 1
414 79 0.3 0.07 0.678 0.658 0.626
GEO DIS PERT UP ALS AMY-
OTROPHIC LATERAL SCLE-
ROSIS C0002736 MOUSE
204 132 2.3 0.40 0.795 0.770 0.734
GEO DIS PERT UP MORBID
OBESITY DOID 11981 HU-
MAN GSE48964 SAMPLE
583
292 115 0.3 0.13 0.759 0.693 0.560
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GEO DIS PERT UP MULTIPLE
SCLEROSIS DOID 2377 HU-
MAN GSE16461 SAMPLE
143 219 1.2 0.41 0.845 0.772 0.821
GEO DRUG DN CISPLATIN
DB00515 HUMAN GSE47856
SAMPLE 3150
162 95 0.3 0.09 0.695 0.700 0.585
GEO DRUG DN CISPLATIN
DB00515 HUMAN GSE47856
SAMPLE 3153
299 75 0.4 0.01 0.624 0.605 0.521
GEO DRUG DN COLOREC-
TAL ADENOCARCINOMA
DB00482 HUMAN GSE11237
SAMPLE
293 107 0.0 0.05 0.765 0.702 0.736
GEO DRUG DN TESTOSTERONE
6013 HUMAN GSE5106
SAMPLE 3206
325 152 1.4 0.25 0.840 0.800 0.804
GEO DRUG PERT OLANZAPINE
RATTUS NORVEGICUS
GPL1355 GDS2608 CHDIR
141 121 2.4 0.38 0.788 0.710 0.736
GEO DRUG UP DICLOFENAC
DB00586 HUMAN GSE54255
SAMPLE 3053
350 123 3.0 0.41 0.694 0.661 0.673
GEO DRUG UP ESTRADIOL 5757
HUMAN GSE26834 SAMPLE
3241
328 120 0.3 0.16 0.784 0.761 0.723
GEO GENE DN ACVR1 KO
MOUSE GSE46689 SAMPLE
2520
234 176 1.1 0.42 0.852 0.810 0.817
GEO GENE DN GATA5 KO
MOUSE GSE47425 SAMPLE
413
311 121 3.0 0.48 0.738 0.656 0.708
GEO GENE DN NR1I3 KO MOUSE
GSE40120 SAMPLE 3066
267 112 0.2 0.10 0.808 0.732 0.745
GEO GENE DN PAFAH1B1 KD
MOUSE GSE35366 SAMPLE
1618
236 75 0.3 0.01 0.642 0.610 0.558
GEO GENE DN SON KD HUMAN
GSE26888 SAMPLE 62
273 119 1.7 0.35 0.811 0.743 0.800
GEO GENE DN TRP53 KO
MOUSE GSE40545 SAMPLE
1829
237 104 0.0 0.03 0.818 0.793 0.734
GEO GENE UP CCAR2 KD HU-
MAN GSE54707 SAMPLE
1072
175 84 4.5 0.42 0.659 0.618 0.601
GEO GENE UP CDH1 KO MOUSE
GSE48131 SAMPLE 2982
297 77 0.2 0.04 0.756 0.726 0.679
GEO GENE UP DMRTA2 OE
MOUSE GSE25179 SAMPLE
2204
175 110 0.2 0.06 0.748 0.689 0.635
GEO GENE UP HNF4A DEPLE-
TION HUMAN GSE29084
SAMPLE 118
351 63 0.0 −0.10 0.685 0.636 0.575
GEO GENE UP ITK KNOCKOUT
MOUSE GSE12465 SAMPLE
1995
257 116 2.4 0.39 0.779 0.757 0.705
GEO GENE UP MIR26B OE HU-
MAN GSE12091 SAMPLE
2978
303 90 0.6 0.19 0.661 0.597 0.497
GEO GENE UP STK19 OE HU-
MAN GSE36036 SAMPLE
1570
335 95 0.2 0.12 0.701 0.603 0.517
GEO GENE UP TWIST1 OE
MOUSE GSE50002 SAMPLE
1075
330 91 1.1 0.29 0.685 0.647 0.549
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GEO LIGAND DN ESTROGEN
MOUSE ALPHA NULL
AORTA GDS3064 LIGAND
26
396 71 0.1 −0.06 0.809 0.813 0.749
GEO LIGAND UP 17BETA
ESTRADIOL MOUSE
PROSTATE GLAND
GSE36630 LIGAND
311 75 0.1 0.03 0.707 0.671 0.529
GEO LIGAND UP FIBROBLAST
GROWTH FACTOR 2 FGF2
HUMAN EMBRYONIC FIB
333 130 2.2 0.37 0.801 0.779 0.756
GEO MCF7 DN MAP2K6 SIRNA
48 HRS GSE53668 MCF7 276
336 145 1.3 0.39 0.849 0.799 0.826
GEO MCF7 UP BORTEZOMIB
VELCADE GSE30931 MCF7
16
360 119 0.7 0.18 0.779 0.716 0.746
GEO MICROBE UP STREPTO-
COCCUS PNEUMONIAE
D39 HUMAN PHARYNGEAL
EPITHE
443 158 0.9 0.24 0.845 0.789 0.805
GEO TF LOF CDX2 20696899
CACO2 LOF HUMAN
GPL570 GSE22572
1,352 91 1.8 0.40 0.653 0.590 0.617
GEO TF LOF GRHL3 16949565
SKIN LOF MOUSE GPL1261
GDS2629 DOWN
168 83 5.0 0.51 0.654 0.584 0.603
GEO VIRUS DN ICSARA
DELTAORF6 60HOUR
GSE33267
286 75 4.6 0.56 0.618 0.551 0.527
GEO VIRUS UP HCV JFH 1
18HOUR GSE20948
294 101 1.6 0.31 0.754 0.647 0.650
GEO VIRUS UP SARS COV
0HOUR GSE47960
290 90 3.4 0.53 0.672 0.565 0.630
GO (test) GO:0000184 118 385 0.0 0.06 0.990 0.996 0.991
GO (test) GO:0000398 239 138 0.1 0.00 0.989 0.993 0.985
GO (test) GO:0003676 255 79 6.9 0.42 0.926 0.885 0.943
GO (test) GO:0003924 280 180 0.0 −0.03 0.990 0.987 0.994
GO (test) GO:0004222 116 77 0.2 −0.04 0.990 0.998 0.995
GO (test) GO:0005096 283 91 0.1 0.07 0.979 0.977 0.973
GO (test) GO:0005739 1,291 87 0.2 0.08 0.930 0.863 0.916
GO (test) GO:0005802 131 91 0.4 0.16 0.913 0.943 0.968
GO (test) GO:0005814 118 82 0.5 0.14 0.918 0.971 0.977
GO (test) GO:0005925 392 201 0.6 0.14 0.962 0.911 0.973
GO (test) GO:0006413 133 353 0.0 0.08 0.987 0.994 0.982
GO (test) GO:0006511 158 138 0.1 0.13 0.979 0.985 0.975
GO (test) GO:0006898 189 125 −0.4 0.00 0.919 0.956 0.919
GO (test) GO:0006914 110 133 0.5 0.12 0.918 0.969 0.948
GO (test) GO:0007156 156 125 0.0 0.09 0.995 0.998 0.992
GO (test) GO:0007186 862 273 0.5 0.03 0.990 0.973 0.980
GO (test) GO:0007204 129 193 0.1 0.07 0.968 0.984 0.971
GO (test) GO:0007568 165 205 0.0 −0.01 0.908 0.901 0.925
GO (test) GO:0008022 177 227 1.7 0.21 0.923 0.906 0.978
GO (test) GO:0010629 136 223 1.5 0.22 0.919 0.910 0.962
GO (test) GO:0016323 183 118 −0.1 −0.10 0.948 0.919 0.980
GO (test) GO:0016567 430 127 0.0 0.02 0.978 0.966 0.984
GO (test) GO:0016887 153 150 0.0 0.00 0.979 0.965 0.988
GO (test) GO:0017124 122 134 0.3 0.07 0.930 0.966 0.990
GO (test) GO:0030168 109 222 −0.3 −0.14 0.978 0.969 0.984
GO (test) GO:0030198 195 133 0.0 0.11 0.975 0.950 0.988
GO (test) GO:0031625 294 209 0.5 0.10 0.938 0.939 0.960
GO (test) GO:0031901 127 107 0.5 0.16 0.917 0.981 0.964
GO (test) GO:0033209 127 190 0.2 0.06 0.989 0.972 0.973
GO (test) GO:0034220 206 87 0.0 0.00 0.990 0.984 0.982
GO (test) GO:0043025 313 146 0.2 0.10 0.891 0.846 0.942
GO (test) GO:0043066 461 187 0.8 0.15 0.944 0.848 0.957
GO (test) GO:0046777 166 406 0.1 0.03 0.988 0.984 0.997
GO (test) GO:0046854 103 159 0.3 0.06 0.979 0.972 0.969
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GO (test) GO:0048471 628 135 1.0 0.27 0.905 0.827 0.964
GO (test) GO:0050900 205 128 0.0 −0.14 0.906 0.959 0.945
GO (test) GO:0051015 145 131 0.0 0.06 0.944 0.971 0.979
GO (test) GO:0051091 103 247 −0.3 −0.15 0.989 0.932 0.989
GO (test) GO:0070374 180 201 0.6 0.13 0.942 0.939 0.949
GO (test) GO:0072562 190 123 0.0 −0.14 0.960 0.945 0.990
LINCS DN CPC001 HCC515 24H RS
17053 HYDROCHLORIDE 10
0
200 114 3.5 0.54 0.726 0.684 0.642
LINCS DN CPC003 VCAP 24H
SERICETIN DIMETHYL
ETHER 10 0
116 102 1.4 0.22 0.693 0.563 0.670
LINCS DN CPC005 A375 24H TRICHO-
STATIN A 10 0
159 108 5.2 0.44 0.728 0.633 0.684
LINCS DN CPC006 A375 24H IMD 0354
10 0
169 114 4.7 0.54 0.722 0.658 0.672
LINCS DN CPC006 A549 24H TRICHO-
STATIN A 10 0
115 101 0.1 0.05 0.738 0.646 0.660
LINCS DN CPC006 HCC515 24H EME-
TINE DIHYDROCHLORIDE
HYDRATE 74
223 115 4.2 0.62 0.707 0.544 0.656
LINCS DN CPC006 LOVO 6H HDAC6
INHIBITOR ISOX 10 0
114 123 5.0 0.52 0.714 0.540 0.699
LINCS DN CPC006 NCIH508 6H MI-
NOXIDIL 10 0
118 109 3.9 0.47 0.728 0.621 0.706
LINCS DN CPC006 PC3 24H
MANUMYCIN A 10 0
228 110 4.1 0.51 0.733 0.724 0.635
LINCS DN CPC006 THP1 6H BRD
K92301463 10 0
122 125 6.6 0.58 0.682 0.641 0.688
LINCS DN CPC006 VCAP 24H BI 2536
10 0
141 111 3.7 0.59 0.723 0.595 0.655
LINCS DN CPC008 A375 24H 2
CHLORO 7 METHOXYPHE-
NOTHIAZINE 10 0
158 103 4.9 0.56 0.681 0.631 0.655
LINCS DN CPC008 VCAP 6H TRICHO-
STATIN A 10 0
159 112 2.2 0.44 0.719 0.605 0.645
LINCS DN CPC009 PC3 24H BRD
K83670234 10 0
104 113 5.5 0.42 0.689 0.636 0.666
LINCS DN CPC010 A375 6H WORT-
MANNIN 10 0
126 121 4.6 0.56 0.706 0.647 0.696
LINCS DN CPC011 A549 6H TRICHO-
STATIN A 10 0
129 112 3.2 0.37 0.654 0.480 0.647
LINCS DN CPC011 MCF7 24H
TOPOTECAN HCL 10
0
126 96 6.1 0.61 0.688 0.605 0.636
LINCS DN CPC011 PC3 24H IDARU-
BICIN HCL 10 0
173 100 0.8 0.25 0.729 0.538 0.651
LINCS DN CPC012 A549 24H TRICHO-
STATIN A 10 0
130 117 2.6 0.32 0.743 0.645 0.700
LINCS DN CPC012 ASC 24H K784 3187
10 0
101 113 2.8 0.38 0.697 0.642 0.646
LINCS DN CPC012 HT29 6H BRD
K87909389 10 0
138 123 6.0 0.58 0.737 0.641 0.695
LINCS DN CPC013 VCAP 24H NP
007374 10 0
106 111 6.9 0.51 0.706 0.563 0.714
LINCS DN CPC014 MCF7 24H BRD
A20697603 10 0
150 135 4.4 0.59 0.719 0.610 0.671
LINCS DN CPC018 A549 24H NSC 3852
10 0
121 111 4.5 0.56 0.710 0.607 0.686
LINCS DN CPC018 HT29 6H MEK1 2
INHIBITOR 10 0
158 103 3.6 0.41 0.713 0.617 0.663
LINCS DN CPD001 MCF7 24H IFEN-
PRODIL TARTRATE 10 0
123 122 4.9 0.52 0.754 0.667 0.726
LINCS DN CPD002 MCF7 24H GEL-
DANAMYCIN 10 0
129 96 4.0 0.47 0.685 0.558 0.685
LINCS DN LJP005 A375 24H CP 724714
10
104 217 3.9 0.33 0.858 0.786 0.848
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LINCS DN LJP005 A375 24H WITH-
AFERIN A 0 04
159 133 1.1 0.26 0.815 0.788 0.735
LINCS DN LJP005 HA1E 24H NVP
AUY922 0 12
136 145 −0.1 −0.02 0.838 0.770 0.787
LINCS DN LJP005 HEPG2 24H GEL-
DANAMYCIN 3 33
151 118 0.3 0.17 0.760 0.667 0.685
LINCS DN LJP005 HEPG2 24H NVP
BEZ235 0 37
129 156 0.4 0.17 0.903 0.812 0.864
LINCS DN LJP005 HS578T 24H PD
0325901 0 37
120 157 0.1 0.07 0.857 0.869 0.801
LINCS DN LJP005 PC3 24H MITOX-
ANTRONE 10
111 162 4.2 0.43 0.803 0.584 0.786
LINCS DN LJP006 A375 24H PF 562271
10
100 145 2.9 0.28 0.792 0.760 0.768
LINCS DN LJP006 A549 24H A443654 0
37
155 110 1.1 0.31 0.773 0.707 0.719
LINCS DN LJP006 HS578T 24H RADI-
CICOL 10
122 122 −0.1 0.04 0.804 0.742 0.774
LINCS DN LJP007 A375 24H NVP
BGT226 0 37
161 116 0.9 0.27 0.804 0.699 0.736
LINCS DN LJP009 MCF7 24H ON 01910
0 37
109 141 1.2 0.28 0.793 0.637 0.754
LINCS DN LJP009 PC3 24H CGP 60474
0 37
124 140 2.9 0.44 0.778 0.699 0.743
MSigDB ACEVEDO FGFR1 TARGETS
IN PROSTATE CANCER
MODEL
597 89 0.3 0.06 0.732 0.670 0.655
MSigDB ACEVEDO LIVER CANCER 1,513 86 0.7 0.15 0.726 0.609 0.701
MSigDB ACEVEDO LIVER CANCER
WITH H3K27ME3
519 82 0.5 0.08 0.628 0.642 0.506
MSigDB ACEVEDO LIVER CANCER
WITH H3K9ME3
257 77 0.1 0.00 0.581 0.564 0.479
MSigDB AGUIRRE PANCREATIC
CANCER COPY NUMBER
534 113 1.4 0.35 0.730 0.657 0.667
MSigDB BERTUCCI MEDULLARY VS
DUCTAL BREAST CANCER
375 102 1.9 0.37 0.694 0.665 0.654
MSigDB BOYAULT LIVER CANCER
SUBCLASS G3
239 125 1.5 0.38 0.805 0.716 0.754
MSigDB CAMPS COLON CANCER
COPY NUMBER
165 107 0.1 0.00 0.690 0.654 0.596
MSigDB CHARAFE BREAST CAN-
CER LUMINAL VS BASAL
834 94 1.0 0.26 0.724 0.652 0.662
MSigDB CHARAFE BREAST CAN-
CER LUMINAL VS MES-
ENCHYMAL
910 87 0.7 0.16 0.726 0.667 0.660
MSigDB CHIANG LIVER CANCER
SUBCLASS CTNNB1
346 88 0.2 0.04 0.766 0.706 0.701
MSigDB CHIANG LIVER CANCER
SUBCLASS PROLIFERA-
TION
356 93 0.1 0.00 0.807 0.776 0.725
MSigDB CHIANG LIVER CANCER
SUBCLASS UNANNOTATED
278 122 1.5 0.40 0.774 0.710 0.708
MSigDB DELYS THYROID CANCER 675 107 0.3 0.10 0.810 0.779 0.761
MSigDB GINESTIER BREAST CAN-
CER 20Q13 AMPLIFICA-
TION
298 92 0.4 0.05 0.709 0.642 0.580
MSigDB GINESTIER BREAST CAN-
CER ZNF217 AMPLIFIED
413 84 0.6 0.09 0.708 0.629 0.671
MSigDB GRADE COLON AND REC-
TAL CANCER
386 128 1.4 0.37 0.762 0.699 0.642
MSigDB GRUETZMANN PANCRE-
ATIC CANCER
561 139 0.9 0.30 0.803 0.740 0.744
MSigDB HOSHIDA LIVER CANCER
LATE RECURRENCE
131 113 5.0 0.44 0.738 0.590 0.715
MSigDB HOSHIDA LIVER CANCER
SURVIVAL
186 116 0.1 0.09 0.767 0.717 0.682
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MSigDB HUMMERICH SKIN CAN-
CER PROGRESSION
188 164 0.4 0.14 0.870 0.759 0.795
MSigDB LAIHO COLORECTAL CAN-
CER SERRATED
198 132 4.4 0.53 0.737 0.669 0.691
MSigDB LEE LIVER CANCER ACOX1 129 89 0.0 0.07 0.801 0.698 0.733
MSigDB LEE LIVER CANCER
CIPROFIBRATE
126 97 −0.1 −0.03 0.830 0.759 0.759
MSigDB LEE LIVER CANCER DENA 134 109 0.1 0.19 0.845 0.779 0.785
MSigDB LEE LIVER CANCER E2F1 126 99 0.0 0.07 0.813 0.684 0.783
MSigDB LEE LIVER CANCER MYC
E2F1
120 105 −0.3 −0.03 0.833 0.783 0.775
MSigDB LEE LIVER CANCER MYC
TGFA
126 98 −0.3 −0.10 0.815 0.748 0.781
MSigDB LEE LIVER CANCER SUR-
VIVAL
360 104 0.9 0.22 0.759 0.727 0.721
MSigDB LINDGREN BLADDER CAN-
CER CLUSTER 1
499 113 2.1 0.40 0.748 0.652 0.686
MSigDB LINDGREN BLADDER CAN-
CER CLUSTER 3
558 113 1.5 0.36 0.756 0.652 0.686
MSigDB LIU PROSTATE CANCER 577 102 0.2 0.04 0.756 0.672 0.672
MSigDB OSMAN BLADDER CANCER 804 107 1.3 0.31 0.739 0.686 0.725
MSigDB POOLA INVASIVE BREAST
CANCER
422 115 0.2 0.13 0.801 0.726 0.722
MSigDB ROESSLER LIVER CANCER
METASTASIS
160 119 5.9 0.52 0.699 0.509 0.676
MSigDB SCHUETZ BREAST CAN-
CER DUCTAL INVASIVE
435 114 0.3 0.17 0.792 0.759 0.730
MSigDB SMID BREAST CANCER
BASAL
1,349 98 0.5 0.15 0.746 0.692 0.661
MSigDB SMID BREAST CANCER LU-
MINAL B
736 102 0.2 0.02 0.784 0.710 0.665
MSigDB SMID BREAST CANCER RE-
LAPSE IN BONE
412 107 0.3 0.14 0.759 0.736 0.681
MSigDB SOTIRIOU BREAST CAN-
CER GRADE 1 VS 3
203 153 −0.1 −0.04 0.871 0.844 0.794
MSigDB STEARMAN LUNG CANCER
EARLY VS LATE
186 130 4.6 0.47 0.743 0.597 0.688
MSigDB SWEET LUNG CANCER
KRAS
921 110 0.6 0.17 0.785 0.727 0.736
MSigDB VANTVEER BREAST CAN-
CER ESR1
407 95 1.3 0.31 0.699 0.587 0.653
MSigDB VANTVEER BREAST CAN-
CER METASTASIS
177 96 0.3 0.09 0.741 0.640 0.640
MSigDB VECCHI GASTRIC CANCER
ADVANCED VS EARLY
138 62 −0.2 −0.08 0.697 0.708 0.701
MSigDB VECCHI GASTRIC CANCER
EARLY
795 90 0.4 0.10 0.705 0.658 0.656
MSigDB WALLACE PROSTATE CAN-
CER RACE
387 100 0.1 0.08 0.759 0.746 0.678
MSigDB WAMUNYOKOLI OVARIAN
CANCER GRADES 1 2
204 77 0.0 −0.03 0.728 0.697 0.649
MSigDB WAMUNYOKOLI OVARIAN
CANCER LMP
464 79 0.6 0.20 0.680 0.633 0.661
MSigDB WANG ESOPHAGUS CAN-
CER VS NORMAL
222 114 0.6 0.20 0.788 0.701 0.688
MSigDB WATANABE RECTAL CAN-
CER RADIOTHERAPY RE-
SPONSIVE
200 160 2.6 0.57 0.771 0.628 0.765
MSigDB WOO LIVER CANCER RE-
CURRENCE
185 120 0.0 0.02 0.890 0.836 0.823
MSigDB ZHANG BREAST CANCER
PROGENITORS
566 106 1.0 0.27 0.750 0.679 0.697
Pathcom 2 2 AMINO 3
METHOXYPHENYL 4H
1 BENZOPYRAN 4 ONE
INHIBITS
233 261 −0.1 −0.06 0.941 0.928 0.922
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Pathcom ABC FAMILY PROTEINS
MEDIATED TRANSPORT
ATP SENSITIVE POTAS
131 79 0.1 0.07 0.996 0.982 0.988
Pathcom CTTTGA V LEF1 Q2
CTTTGT V LEF1 Q2
322 128 0.2 0.09 0.799 0.719 0.701
Pathcom CTTTGT V LEF1 Q2 1,493 104 0.8 0.23 0.714 0.662 0.651
Pathcom GGGTGGRR V PAX4 03 900 115 1.2 0.30 0.735 0.686 0.690
Pathcom RCGCANGCGY V NRF1 Q6 V
NRF1 Q6
203 102 3.0 0.42 0.711 0.639 0.678
Pathcom RGAANNTTC V HSF1 01 209 107 4.9 0.57 0.717 0.583 0.624
Pathcom SGCGSSAAA V E2F1DP2 01
V E2F1DP1RB 01
120 112 0.4 0.14 0.815 0.786 0.788
Pathcom TGACCTTG V SF1 Q6 V SF1
Q6
136 96 −0.2 −0.08 0.694 0.583 0.638
Pathcom TGACCTY V ERR1 Q2 811 104 0.9 0.25 0.701 0.635 0.653
Pathcom TGACCTY V ERR1 Q2 V
ERR1 Q2
170 102 0.1 0.00 0.713 0.623 0.644
Pathcom TGCCAAR V NF1 Q6 544 102 1.1 0.30 0.713 0.606 0.590
Pathcom TGF BETA RECEPTOR 185 363 0.2 0.09 0.964 0.956 0.921
Pathcom V AP4 Q6 01 134 128 2.8 0.41 0.750 0.647 0.692
Pathcom V AREB6 01 100 121 0.6 0.24 0.680 0.589 0.615
Pathcom V CEBPB 01 179 126 3.5 0.45 0.730 0.663 0.649
Pathcom V CREB Q3 140 127 4.6 0.56 0.702 0.610 0.695
Pathcom V DBP Q6 248 106 −0.1 −0.04 0.747 0.675 0.628
Pathcom V EN1 01 104 151 0.4 0.15 0.764 0.677 0.743
Pathcom V ER Q6 01 225 115 1.1 0.32 0.726 0.597 0.642
Pathcom V FOXD3 01 188 123 1.7 0.43 0.754 0.759 0.684
Pathcom V GATA2 01 100 153 6.0 0.44 0.697 0.680 0.694
Pathcom V HIF1 Q3 V HIF1 Q5 126 117 0.2 0.07 0.732 0.665 0.692
Pathcom V HNF6 Q6 228 118 0.4 0.16 0.749 0.655 0.631
Pathcom V HOXA4 Q2 239 135 0.6 0.24 0.761 0.698 0.635
Pathcom V IRF1 01 137 119 2.1 0.29 0.738 0.612 0.706
Pathcom V IRF2 01 120 109 3.2 0.45 0.721 0.648 0.714
Pathcom V LBP1 Q6 199 92 2.7 0.44 0.719 0.638 0.611
Pathcom V LMO2COM 01 220 105 3.2 0.44 0.750 0.648 0.617
Pathcom V MYB Q6 107 116 7.8 0.57 0.703 0.686 0.657
Pathcom V MYCMAX 02 106 117 1.4 0.24 0.718 0.649 0.699
Pathcom V PAX4 02 143 86 −0.4 −0.09 0.719 0.710 0.573
Pathcom V PTF1BETA Q6 221 119 1.6 0.29 0.732 0.623 0.655
Pathcom V SOX9 B1 113 132 0.0 0.13 0.771 0.645 0.720
Pathcom V SP3 Q3 234 114 2.1 0.38 0.718 0.678 0.620
Pathcom V SRY 02 194 133 −0.2 −0.10 0.780 0.672 0.662
Pathcom V TAL1BETAITF2 01 217 91 0.2 0.07 0.732 0.646 0.584
Pathcom V TCF11 01 242 118 1.4 0.36 0.711 0.635 0.609
Pathcom V TFIIA Q6 225 119 1.3 0.31 0.733 0.631 0.632
Pathcom WNT 101 302 −0.4 −0.14 0.970 0.976 0.946
Reactome HSA 112314 154 127 0.0 0.02 0.980 0.981 0.961
Reactome HSA 112412 265 204 0.1 0.06 0.954 0.983 0.923
Reactome HSA 1428517 177 113 0.0 −0.02 0.976 0.998 0.960
Reactome HSA 1500931 141 156 1.5 0.26 0.984 0.991 0.980
Reactome HSA 162906 260 155 0.3 0.09 0.922 0.979 0.906
Reactome HSA 1630316 125 70 −0.3 −0.04 0.986 0.999 0.975
Reactome HSA 166520 510 207 0.1 0.02 0.968 0.964 0.907
Reactome HSA 168179 106 354 0.1 0.02 0.944 0.992 0.946
Reactome HSA 1852241 418 112 0.3 0.12 0.960 0.962 0.938
Reactome HSA 194840 148 120 −0.1 −0.04 0.995 0.997 0.981
Reactome HSA 195258 314 151 0.0 0.01 0.979 0.967 0.957
Reactome HSA 198203 135 260 0.2 0.03 0.981 0.955 0.963
Reactome HSA 202424 156 165 0.0 −0.02 0.988 0.984 0.986
Reactome HSA 211945 114 109 0.0 0.01 0.975 0.994 0.985
Reactome HSA 2172127 424 220 −0.1 −0.01 0.895 0.972 0.897
Reactome HSA 2428924 319 212 0.1 0.05 0.962 0.981 0.893
Reactome HSA 2555396 214 144 0.1 0.05 0.949 0.991 0.927
Reactome HSA 2871796 329 181 0.1 0.05 0.883 0.973 0.884
Reactome HSA 373080 101 132 0.1 0.05 0.996 0.999 0.988
Reactome HSA 375165 302 189 0.1 0.05 0.962 0.977 0.898
Reactome HSA 397014 204 126 0.5 0.20 0.977 0.991 0.972
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Reactome HSA 418594 280 113 0.3 0.04 0.970 0.993 0.928
Reactome HSA 446652 111 258 0.0 0.05 0.967 0.998 0.945
Reactome HSA 448424 328 231 0.1 0.05 0.960 0.981 0.898
Reactome HSA 453279 165 252 0.0 −0.01 0.951 0.993 0.903
Reactome HSA 5368287 103 78 0.0 0.03 0.985 0.996 0.943
Reactome HSA 5578749 105 135 0.0 0.02 0.982 0.996 0.994
Reactome HSA 5683057 317 212 0.2 0.09 0.956 0.978 0.849
Reactome HSA 5684996 271 205 0.1 0.07 0.961 0.983 0.889
Reactome HSA 6803157 107 26 3.5 0.21 0.952 0.981 0.939
Reactome HSA 6811434 104 137 0.0 0.03 0.986 0.995 0.982
Reactome HSA 68886 347 138 0.0 0.03 0.931 0.988 0.940
Reactome HSA 69002 102 207 −0.3 −0.14 0.945 0.999 0.915
Reactome HSA 73864 133 125 0.1 0.04 0.983 0.996 0.930
Reactome HSA 74752 349 190 0.1 0.03 0.952 0.979 0.917
Reactome HSA 8853659 290 205 0.1 0.06 0.961 0.978 0.904
Reactome HSA 8953854 804 142 0.1 0.02 0.926 0.969 0.887
Reactome HSA 912526 276 205 0.2 0.07 0.951 0.980 0.887
Reactome HSA 975957 126 372 0.0 0.01 0.995 0.995 0.985
Reactome HSA 983169 445 133 0.0 0.02 0.891 0.975 0.912
TargetScan AAAGACA MIR 511 169 125 2.6 0.38 0.729 0.621 0.641
TargetScan AAAGGAT MIR 501 106 110 0.9 0.25 0.755 0.645 0.712
TargetScan AAGCACA MIR 218 337 120 0.5 0.25 0.754 0.686 0.690
TargetScan AAGCACT MIR 520F 196 119 1.1 0.30 0.766 0.623 0.677
TargetScan ACACTGG MIR 199A MIR
199B
136 148 2.9 0.30 0.794 0.706 0.741
TargetScan ACATTCC MIR 1 MIR 206 247 125 3.0 0.44 0.762 0.688 0.705
TargetScan ACCATTT MIR 522 145 133 1.4 0.27 0.775 0.675 0.725
TargetScan ACTGAAA MIR 30A 3P MIR
30E 3P
164 146 0.6 0.18 0.793 0.679 0.713
TargetScan ACTGCCT MIR 34B 190 112 0.5 0.21 0.755 0.693 0.687
TargetScan ACTGTGA MIR 27A MIR 27B 388 111 2.5 0.46 0.757 0.691 0.626
TargetScan AGCACTT MIR 93 MIR 302A
MIR 302B MIR 302C MIR
302D M
282 121 0.3 0.09 0.767 0.723 0.734
TargetScan AGCATTA MIR 155 116 134 3.0 0.26 0.798 0.727 0.752
TargetScan ATAAGCT MIR 21 103 135 2.3 0.39 0.798 0.827 0.791
TargetScan ATATGCA MIR 448 190 120 0.6 0.25 0.727 0.652 0.635
TargetScan ATGAAGG MIR 205 134 113 0.4 0.20 0.755 0.679 0.707
TargetScan ATGTAGC MIR 221 MIR 222 114 127 0.3 0.18 0.743 0.657 0.751
TargetScan CACTGCC MIR 34A MIR 34C
MIR 449
252 100 1.1 0.28 0.744 0.672 0.599
TargetScan CAGCACT MIR 512 3P 134 112 −0.1 −0.07 0.744 0.726 0.642
TargetScan CATGTAA MIR 496 152 115 0.1 0.06 0.740 0.667 0.682
TargetScan CCTGCTG MIR 214 194 103 −0.2 0.01 0.720 0.628 0.665
TargetScan CCTGTGA MIR 513 109 112 5.5 0.64 0.702 0.690 0.687
TargetScan CTCTGGA MIR 520A MIR
525
133 122 1.9 0.27 0.715 0.664 0.732
TargetScan CTTTGCA MIR 527 202 130 2.5 0.37 0.776 0.703 0.733
TargetScan GACTGTT MIR 212 MIR 132 133 101 1.9 0.34 0.758 0.657 0.728
TargetScan GAGCCAG MIR 149 122 113 4.4 0.50 0.734 0.583 0.683
TargetScan GAGCTGG MIR 337 133 98 0.2 0.05 0.700 0.579 0.676
TargetScan GCATTTG MIR 105 150 114 5.5 0.46 0.724 0.557 0.714
TargetScan GGCACTT MIR 519E 108 135 0.4 0.15 0.789 0.718 0.747
TargetScan GGGACCA MIR 133A MIR
133B
176 121 1.9 0.33 0.676 0.699 0.599
TargetScan GGGCATT MIR 365 101 117 −0.1 0.00 0.777 0.698 0.741
TargetScan GTACTGT MIR 101 219 138 1.6 0.32 0.792 0.687 0.729
TargetScan GTGCAAA MIR 507 109 149 0.4 0.20 0.781 0.642 0.742
TargetScan TCTCTCC MIR 185 102 121 0.1 −0.01 0.742 0.565 0.696
TargetScan TGCACTT MIR 519C MIR
519B MIR 519A
377 123 1.2 0.33 0.759 0.715 0.698
TargetScan TGCCTTA MIR 124A 474 95 0.7 0.21 0.761 0.695 0.681
TargetScan TGCTGCT MIR 15A MIR 16
MIR 15B MIR 195 MIR 424
MIR 4
518 118 0.8 0.27 0.735 0.669 0.662
TargetScan TGGTGCT MIR 29A MIR
29B MIR 29C
438 109 0.5 0.19 0.745 0.683 0.661
Continued on next page→
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Collection Gene Set Size Median
Degree
∆Med ∆200+ MAPR
AUC
DRaWR
AUC
LASSO
AUC
TargetScan TGTTTAC MIR 30A 5P MIR
30C MIR 30D MIR 30B MIR
30E 5
494 105 0.3 0.15 0.752 0.675 0.667
TargetScan TTTGCAG MIR 518A 2 179 123 0.2 0.11 0.782 0.696 0.713
TargetScan TTTTGAG MIR 373 195 126 4.1 0.48 0.765 0.658 0.722
End of table.
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APPENDIX B
COMPARISONS OF SIMILARITY RANK
AND MUTATION RATES FOR GENE
FAMILIES IN BTNR
Two tables are presented here for each of the following three gene families
found to be highly ranked for BTNR: claudins, kallikreins and collagen type
N alpha chains.
The first table in each pair presents the gene name and brief description,
followed and sorted by the GeneSet MAPR similarity rank (out of 23,782).
It also shows whether a gene was part of the original 323 genes in BTNR
as well as the log fold change in DE and p-value measured as part of the
phenotype created during the BEAUTY study. Finally, for of the other 9
cancer gene sets tested for comparison, the table shows how many sets in
which the gene appeared and the median MAPR similarity rank.
The second table in each pair again shows the gene name, MAPR similarity
rank, and membership in BTNR. It also shows SNV and CNV mutation rates
measured during the BEAUTY study for participants with triple-negative
breast cancer, separated by non-responders (nR) and pathological complete
response (pCR). Additionally, it shows mutation rates from TCGA across
breast cancer cases (BC) and all cases, as well as whether the gene is identi-
fied by COSMIC as a Tier 1 or Tier 2 cancer gene.
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Table B.1: Summary of Ranked Claudins for BTNR using GeneSet MAPR,
Part 1 of 2
Gene Name Description MAPR
rank
BTNR
in set
BTNR
logFC
BTNR
p-val
Others
in set
Others
med rnk
CLDN5 claudin 5 2 0.04 0.901 1 2, 998
CLDN22 claudin 22 4 6, 280
CLDN2 claudin 2 9 y 0.99 0.023 1 1, 046
CLDN8 claudin 8 17 y 1.11 0.029 2 8, 759
CLDN17 claudin 17 22 7, 783
CLDN23 claudin 23 23 −0.31 0.348 9, 401
CLDN19 claudin 19 32 0.71 0.189 7, 434
CLDN15 claudin 15 46 0.20 0.346 4, 917
CLDN4 claudin 4 69 0.77 0.005 6, 374
CLDN11 claudin 11 71 0.63 0.091 7, 601
CLDN3 claudin 3 75 0.68 0.100 5, 029
CLDN18 claudin 18 78 y 0.85 0.012 4, 933
CLDN10 claudin 10 117 y 1.28 0.054 2 2, 268
CLDN14 claudin 14 119 −0.16 0.682 6, 328
CLDN16 claudin 16 196 0.57 0.233 6, 160
CLDN7 claudin 7 226 0.22 0.512 2, 610
CLDN12 claudin 12 240 0.33 0.033 1 4, 654
CLDN6 claudin 6 284 y 1.58 0.002 1 7, 542
CLDN9 claudin 9 373 −0.88 0.038 5, 199
CLDN1 claudin 1 386 y 0.88 0.079 2 4, 059
CLDN20 claudin 20 622 0.11 0.773 1 9, 639
CLDN25 claudin 25 688 10, 451
CLDN24 claudin 24 3, 674 17, 373
CLDND2 claudin domain contain-
ing 2
9, 722 −0.57 0.041 17, 026
CLDN34 claudin 34 10, 532 17, 939
CLDND1 claudin domain contain-
ing 1
11, 639 0.05 0.729 16, 056
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Table B.2: Summary of Ranked Claudins for BTNR using GeneSet MAPR,
Part 2 of 2
Gene Name MAPR
rank
BTNR
in set
SNV
nR
SNV
pCR
CNV
nR
CNV
pCR
TCGA,
BC
TCGA,
all
COSMIC
Tier
CLDN5 2 0.011 0.000 0.005
CLDN22 4 0.005
CLDN2 9 y 0.010
CLDN8 17 y 0.011
CLDN17 22 0.011
CLDN23 23 0.034 0.023 0.006
CLDN19 32 0.008
CLDN15 46 0.006
CLDN4 69 0.010
CLDN11 71 0.045 0.023 0.008
CLDN3 75 0.003
CLDN18 78 y 0.014
CLDN10 117 y 0.012
CLDN14 119 0.006
CLDN16 196
CLDN7 226 0.006
CLDN12 240 0.010
CLDN6 284 y 0.009
CLDN9 373
CLDN1 386 y 0.008
CLDN20 622 0.006
CLDN25 688
CLDN24 3, 674
CLDND2 9, 722
CLDN34 10, 532
CLDND1 11, 639
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Table B.3: Summary of Ranked Kallikreins for BTNR using GeneSet
MAPR, Part 1 of 2
Gene Name Description MAPR
rank
BTNR
in set
BTNR
logFC
BTNR
p-val
Others
in set
Others
med rnk
KLK13 kallikrein related pepti-
dase 13
20 y −1.45 0.013 1 7, 699
KLK8 kallikrein related pepti-
dase 8
28 y −2.00 0.002 3 7, 367
KLK12 kallikrein related pepti-
dase 12
30 10, 077
KLK7 kallikrein related pepti-
dase 7
35 y −2.32 0.000 4 532
KLK5 kallikrein related pepti-
dase 5
37 y −2.57 0.000 4 2, 007
KLK14 kallikrein related pepti-
dase 14
64 y −1.51 0.012 1 6, 276
KLK4 kallikrein related pepti-
dase 4
76 0.70 0.158 1, 682
KLK6 kallikrein related pepti-
dase 6
105 y −2.30 0.000 4 1, 787
KLK15 kallikrein related pepti-
dase 15
125 3, 921
KLK10 kallikrein related pepti-
dase 10
136 y −2.14 0.001 5 6, 069
KLK11 kallikrein related pepti-
dase 11
152 −0.37 0.602 3, 035
KLK1 kallikrein 1 163 −0.50 0.260 1, 956
KLK2 kallikrein related pepti-
dase 2
270 2, 082
KLKB1 kallikrein B1 391 0.56 0.082 1, 846
KLK3 kallikrein related pepti-
dase 3
1, 012 3, 992
KLK9 kallikrein related pepti-
dase 9
10, 373 18, 931
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Table B.4: Summary of Ranked Kallikreins for BTNR using GeneSet
MAPR, Part 2 of 2
Gene Name MAPR
rank
BTNR
in set
SNV
nR
SNV
pCR
CNV
nR
CNV
pCR
TCGA,
BC
TCGA,
all
COSMIC
Tier
KLK13 20 y 0.011
KLK8 28 y 0.014
KLK12 30 0.013
KLK7 35 y 0.008
KLK5 37 y 0.013
KLK14 64 y 0.000 0.023 0.007
KLK4 76 0.014
KLK6 105 y 0.013
KLK15 125 0.016
KLK10 136 y 0.008
KLK11 152 0.012
KLK1 163 0.000 0.023
KLK2 270 0.012 1
KLKB1 391 0.016
KLK3 1, 012
KLK9 10, 373
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Table B.5: Summary of Ranked Collagen Type N Alpha Chains for BTNR
using GeneSet MAPR, Part 1 of 2
Gene Name Description MAPR
rank
BTNR
in set
BTNR
logFC
BTNR
p-val
Others
in set
Others
med rnk
COL20A1 col. type XX α1 chain 25 3, 014
COL9A3 col. type IX α3 chain 40 y 1.38 0.006 4 329
COL9A2 col. type IX α2 chain 48 0.71 0.008 1 497
COL27A1 col. type XXVII α1
chain
55 0.95 0.000 1 724
COL28A1 col. type XXVIII α1
chain
57 y 0.57 0.234 449
COL22A1 col. type XXII α1 chain 59 −1.05 0.054 1 1, 317
COL6A6 col. type VI α6 chain 62 −0.32 0.462 1, 823
COL6A5 col. type VI α5 chain 67 y −2.02 0.003 1 2, 183
COL24A1 col. type XXIV α1 chain 72 0.54 0.120 676
COL10A1 col. type X α1 chain 88 0.65 0.186 1 376
COL12A1 col. type XII α1 chain 89 −0.21 0.585 258
COL25A1 col. type XXV α1 chain 95 −0.06 0.864 1 1, 380
COL4A1 col. type IV α1 chain 96 −0.07 0.776 658
COL4A4 col. type IV α4 chain 98 −0.38 0.200 1, 586
COL4A5 col. type IV α5 chain 100 0.01 0.966 3 824
COL21A1 col. type XXI α1 chain 106 0.23 0.543 1, 776
COL9A1 col. type IX α1 chain 113 y 1.86 0.002 2 735
COL4A6 col. type IV α6 chain 120 y 0.75 0.088 1 1, 395
COL23A1 col. type XXIII α1 chain 138 −0.44 0.182 2, 543
COL14A1 col. type XIV α1 chain 155 0.38 0.351 2 864
COL8A2 col. type VIII α2 chain 156 −0.08 0.781 1, 268
COL6A3 col. type VI α3 chain 166 0.04 0.885 3 2, 386
COL11A1 col. type XI α1 chain 170 0.09 0.871 2 208
COL6A2 col. type VI α2 chain 171 −0.41 0.069 1 1, 016
COL17A1 col. type XVII α1 chain 185 0.09 0.870 197
COL5A3 col. type V α3 chain 191 0.13 0.644 711
COL5A2 col. type V α2 chain 198 −0.03 0.918 2 2, 157
COL2A1 col. type II α1 chain 233 y 1.74 0.020 2 646
COL1A2 col. type I α2 chain 267 −0.05 0.888 2 730
COL13A1 col. type XIII α1 chain 271 0.14 0.629 2, 581
COL16A1 col. type XVI α1 chain 274 0.13 0.665 1 1, 615
COL6A1 col. type VI α1 chain 278 −0.11 0.633 1, 249
COL18A1 col. type XVIII α1 chain 282 −0.03 0.881 1 459
COL4A2 col. type IV α2 chain 340 −0.11 0.592 2 1, 458
COL5A1 col. type V α1 chain 348 −0.22 0.499 1 658
COL3A1 col. type III α1 chain 378 0.05 0.869 2 525
COL4A3 col. type IV α3 chain 390 −0.06 0.849 1, 383
COL15A1 col. type XV α1 chain 402 0.35 0.233 755
COL1A1 col. type I α1 chain 411 −0.06 0.854 3 627
COL7A1 col. type VII α1 chain 419 −0.12 0.732 1 693
COL8A1 col. type VIII α1 chain 472 0.56 0.210 1, 701
COL26A1 col. type XXVI α1 chain 734 3, 512
COL19A1 col. type XIX α1 chain 1, 103 −0.51 0.378 7, 225
COL11A2 col. type XI α2 chain 3, 108 7, 185
(Omitted: 3 items of higher rank)
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Table B.6: Summary of Ranked Collagen Type N Alpha Chains for BTNR
using GeneSet MAPR, Part 2 of 2
Gene Name MAPR
rank
BTNR
in set
SNV
nR
SNV
pCR
CNV
nR
CNV
pCR
TCGA,
BC
TCGA,
all
COSMIC
Tier
COL20A1 25 0.029
COL9A3 40 y 0.018
COL9A2 48 0.018
COL27A1 55 0.035
COL28A1 57 y 0.027
COL22A1 59 0.011 0.000 0.068 0.364 0.028 0.071
COL6A6 62 0.026 0.059
COL6A5 67 y 0.036 0.040
COL24A1 72 0.039
COL10A1 88 0.013
COL12A1 89 0.023 0.023 0.034 0.065
COL25A1 95 0.026
COL4A1 96 0.042
COL4A4 98 0.021 0.048
COL4A5 100 0.011 0.000 0.028 0.048
COL21A1 106 0.000 0.023 0.032
COL9A1 113 y 0.034
COL4A6 120 y 0.019 0.037
COL23A1 138 0.014
COL14A1 155 0.000 0.045 0.034 0.182 0.030 0.050
COL8A2 156 0.011
COL6A3 166 0.011 0.000 0.034 0.083
COL11A1 170 0.023 0.000 0.019 0.081
COL6A2 171 0.036
COL17A1 185 0.000 0.023 0.032
COL5A3 191 0.023 0.000 0.019 0.043
COL5A2 198 0.000 0.023 0.017 0.043
COL2A1 233 y 0.011 0.000 0.034 1
COL1A2 267 0.000 0.045 0.018 0.047
COL13A1 271
COL16A1 274 0.000 0.023 0.032
COL6A1 278 0.000 0.023 0.024
COL18A1 282 0.019 0.030
COL4A2 340 0.038
COL5A1 348 0.000 0.023 0.023 0.059
COL3A1 378 0.011 0.023 0.047 2
COL4A3 390
COL15A1 402
COL1A1 411 0.031 1
COL7A1 419 0.000 0.023 0.023 0.055
COL8A1 472
COL26A1 734 0.011
COL19A1 1, 103 0.018 0.042
COL11A2 3, 108
(Omitted: 3 items of higher rank)
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APPENDIX C
COMPARISON OF TERM ENRICHMENT
FOR BTNR BEFORE AND AFTER
GENESET MAPR
Table C.1 contains annotation terms which were in the top 100 terms re-
turned by GSEA, after running GeneSet MAPR on the BTNR set. Terms
were filtered out that had a median rank of 100 or better over the other 9
compared gene sets, as these were considered broadly applicable to cancer
sets and therefore less interesting. The first three columns indicate the an-
notation term name, brief description, and size. The next three show the
rank returned from GSEA when using the original BTNR set, the MAPR
similarity ranking, and the median rank over 9 other cancer sets. The last
four columns show, for each annotation term, the proportion of genes from
the group indicated in the row header that appear in that term. The four
groups are the Claudin family, the Kallikrein family, the Collagen Type N
Alpha Chain family, and the top 323 genes as ranked by MAPR.
Table C.1: Top 100 Enriched Annotation Terms from GSEA after Using
GeneSet MAPR, Omitting Those Common to Other Gene Sets
Term Description Size BTNR
rank
MAPR
rank
Med
rank
CLD KLK COL MAPR
323
GO:0004252 serine-type endopepti-
dase activity
241 1,112 3 215 – 0.93 – 0.17
PF00089.21 Trypsin 123 768 4 265 – 1.00 – 0.16
GO:0007156 homophilic cell ad-
hesion via plasma
membrane adhesion
molecules
160 421 5 236 – – – 0.15
PF00028.12 Cadherin 116 365 7 392 – – – 0.14
PF00008.22 EGF 171 505 8 106 – – – 0.08
PF08266.7 Cadherin 2 96 661 9 464 – – – 0.13
PF09342.6 DUF1986 94 744 10 321 – 0.93 – 0.13
GO:0034765 regulation of ion trans-
membrane transport
118 1,720 11 441 – – – 0.03
GO:0006811 ion transport 167 532 13 286 0.13 – – 0.02
Continued on next page →
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Table C.1 – continued from previous page
Term Description Size BTNR
rank
MAPR
rank
Med
rank
CLD KLK COL MAPR
323
PF00520.26 Ion trans 121 856 14 514 – – – 0.02
PF13365.1 Trypsin 2 80 645 15 414 – 0.73 – 0.11
PF01391.13 Collagen 87 1,096 17 291 – – 0.94 0.08
GO:0071805 potassium ion trans-
membrane transport
136 1,947 18 597 – – – 0.00
PF07645.10 EGF CA 100 718 19 188 – – – 0.06
PF07885.11 Ion trans 2 81 1,505 20 549 – – – 0.01
GO:0030574 collagen catabolic pro-
cess
75 684 21 162 – 0.07 0.81 0.09
PF12947.2 EGF 3 88 1,017 22 245 – – – 0.05
GO:0004222 metalloendopeptidase
activity
135 3,197 23 475 – – – 0.06
GO:0007268 chemical synaptic
transmission
420 190 24 134 – – – 0.02
PF12662.2 cEGF 102 469 26 179 – – – 0.04
PF13583.1 Reprolysin 4 59 1,198 28 384 – – – 0.03
path:map04974 Protein digestion and
absorption
90 1,635 29 278 – – 0.74 0.07
GO:0008201 heparin binding 157 442 30 116 – – 0.09 0.03
PF07690.11 MFS 1 136 1,899 31 1,006 – – – 0.01
PF13582.1 Reprolysin 3 58 1,488 32 468 – – – 0.03
PF12661.2 hEGF 107 1,221 33 342 – – – 0.03
PF13519.1 VWA 2 69 1,730 34 808 – – 0.26 0.05
PF00041.16 fn3 193 251 35 312 – – 0.09 0.02
PF02210.19 Laminin G 2 62 1,700 36 400 – – 0.28 0.03
PF00092.23 VWA 71 1,252 37 668 – – 0.26 0.05
GO:0004867 serine-type endopepti-
dase inhibitor activity
102 – 38 301 – – 0.06 0.06
path:map04080 Neuroactive ligand-
receptor interaction
276 1,133 39 142 – – – 0.01
PF13574.1 Reprolysin 2 52 1,382 40 476 – – – 0.02
GO:0005604 basement membrane 79 1,059 41 204 – – 0.19 0.05
GO:0070588 calcium ion transmem-
brane transport
153 478 42 489 – – – 0.01
GO:0035725 sodium ion transmem-
brane transport
106 1,946 43 1,247 – – – 0.02
GO:0008076 voltage-gated potas-
sium channel complex
93 1,675 44 579 – – – –
path:map04514 Cell adhesion
molecules (CAMs)
141 710 45 203 0.92 – – 0.04
PF13688.1 Peptidase M84 54 1,614 46 445 – – – 0.02
GO:1902476 chloride transmem-
brane transport
116 1,601 47 808 – – – 0.01
PF07974.8 EGF 2 105 929 48 294 – – – 0.03
PF08016.7 PKD channel 59 1,774 49 1,313 – – – 0.02
PF00413.19 Peptidase M10 46 1,581 50 356 – – – 0.03
GO:0010951 negative regulation of
endopeptidase activity
202 – 51 311 – – 0.09 0.07
Continued on next page →
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Term Description Size BTNR
rank
MAPR
rank
Med
rank
CLD KLK COL MAPR
323
GO:0006810 transport 408 224 52 297 – – – 0.03
GO:0005581 collagen trimer 70 1,095 53 588 – – 0.53 0.06
GO:0005201 extracellular matrix
structural constituent
60 1,773 54 301 – – 0.45 0.07
GO:0005796 Golgi lumen 88 1,964 55 410 – – – 0.01
unmapped C2 set 2 226 2,832 56 281 – – – 0.01
PF13768.1 VWA 3 44 2,616 57 939 – – 0.23 0.05
GO:0008236 serine-type peptidase
activity
59 2,511 58 1,047 – 0.53 – 0.04
PF00822.15 PMP22 Claudin 60 1,333 59 2,631 1.00 – – 0.06
PF00083.19 Sugar tr 74 2,831 60 1,699 – – – 0.00
PF02480.11 Herpes gE 151 739 61 666 – – – 0.04
PF00090.14 TSP 1 62 1,098 62 508 – – – 0.02
PF13903.1 Claudin 2 82 1,426 64 3,371 1.00 – – 0.06
PF13306.1 LRR 5 107 1,091 66 921 – – – 0.01
PF13385.1 Laminin G 3 65 1,632 67 527 – – 0.28 0.03
PF07648.10 Kazal 2 51 2,897 68 1,876 – – – 0.03
GO:0005178 integrin binding 104 406 69 148 – – 0.09 0.02
GO:0001501 skeletal system devel-
opment
136 321 70 228 – – 0.21 0.03
PF00046.24 Homeobox 246 2,715 71 203 – – – –
PF01400.19 Astacin 26 2,748 72 384 – – – 0.03
PF01462.13 LRRNT 73 2,507 73 1,061 – – – 0.01
GO:0045211 postsynaptic mem-
brane
210 1,025 74 417 – – – 0.02
GO:0006814 sodium ion transport 88 1,299 75 1,618 – – – 0.01
GO:0034220 ion transmembrane
transport
293 273 76 248 – – – 0.01
PF01421.14 Reprolysin 41 2,533 77 1,081 – – – 0.01
PF01562.14 Pep M12B propep 39 2,557 78 1,089 – – – 0.01
PF00050.16 Kazal 1 49 3,615 79 2,157 – – – 0.03
GO:0016323 basolateral plasma
membrane
186 409 80 273 0.13 – – 0.02
GO:0006813 potassium ion trans-
port
88 2,206 81 685 – – – 0.01
GO:0016324 apical plasma mem-
brane
274 377 82 156 0.08 – – 0.02
GO:0005245 voltage-gated calcium
channel activity
50 3,216 83 1,337 – – – 0.01
PF00054.18 Laminin G 1 44 2,822 85 503 – – 0.09 0.01
PF13520.1 AA permease 2 28 918 86 3,441 – – – 0.01
GO:0005254 chloride channel activ-
ity
64 3,007 87 1,563 – – – 0.01
GO:0005249 voltage-gated potas-
sium channel activity
63 4,199 88 1,061 – – – 0.00
GO:0030054 cell junction 444 142 89 268 – – – 0.02
PF02932.11 Neur chan memb 57 2,249 90 1,240 – – – 0.01
GO:0005518 collagen binding 59 1,788 91 429 – – 0.04 0.01
Continued on next page →
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Term Description Size BTNR
rank
MAPR
rank
Med
rank
CLD KLK COL MAPR
323
PF01049.12 Cadherin C 29 2,443 92 839 – – – 0.01
GO:0016338 calcium-independent
cell-cell adhesion
via plasma mem-
brane cell-adhesion
molecules
21 462 94 1,883 0.88 – – 0.05
GO:0042391 regulation of mem-
brane potential
78 1,500 96 936 – – – 0.02
PF01094.23 ANF receptor 39 2,654 97 1,303 – – – 0.00
path:map04610 Complement and co-
agulation cascades
69 1,857 99 165 – 0.07 – 0.02
GO:0010862 positive regulation
of pathway-restricted
SMAD protein phos-
phorylation
47 3,042 100 583 – – – 0.01
End of table.
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